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Aaron Marcus Shaw 
 
ADVANCING THE SAFETY OF LENTIVIRAL VECTOR MEDIATED GENE THERAPY 
 
Lentiviral vector mediated gene therapy has made great strides in recent years 
with several successful clinical trials. However, adverse events encountered with some 
early trials have highlighted the necessity to improve upon its safety. Improvements can 
range from early steps in vector production to evaluation of insertion sites post-
transduction. We have evaluated an FDA approved DNase for removal of residual 
plasmid DNA during vector production, developed novel non-integrating lentiviral 
vectors and employed modified insertion site analysis post-transduction to improve the 
safety of lentiviral vector mediated gene therapy.  
To prevent the exposure of gene therapy patients to HIV-1 DNA it is essential to 
remove residual plasmid DNA during vector production. We evaluated a recombinant 
human DNase which has been FDA approved for use in patients as an alternative to a 
bacterially derived DNase. Our results indicate this DNase is an effective alternative with 
a potentially safer profile for use in patients.  
The ability of lentiviral vectors to stably integrate their genome into a host cell’s 
DNA can have negative side-effects due to the risk of insertional mutagenesis. Non-
integrating lentiviral vectors have been developed to alleviate this risk in applications 
where integration is not necessary. However, a low frequency of illegitimate integration 
persists when using these vectors. We have developed a novel non-integrating vector 
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mutation and evaluated the efficacy of combining it with other mutations for reducing 
the frequency of illegitimate integration. We demonstrate that combining mutations 
that inhibit integration can further reduce the frequency of illegitimate integration.  
Several methodologies have been developed for evaluating the insertion sites of 
normal integrating lentiviral vectors. Illegitimate integration by non-integrating vectors 
demonstrates mechanisms which result in insertions and/or deletions at the vector-
genome junction. Current methods lack the sensitivity to account for these variables in a 
high-throughput manner. We have adapted modifications to current methods to 
improve the capture of these variable insertion sites for analysis.  
The results of these studies improve the safety of lentiviral vector mediated gene 
therapy by improving the purity of the vector product, providing a safer vector for non-
integrase mediated applications, and allowing more sensitive analysis of insertion sites 
post-transduction. 
 
Kenneth Cornetta, MD, Chair 
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I. Introduction 
 
A. Design and production of lentiviral vectors 
“Adapted from Shaw A, Cornetta K. Design and Potential of Non-Integrating Lentiviral 
Vectors. Biomedicines. 2014; 2(1):14-35” 
 
Gene therapy using the current third generation of lentiviral vectors (LV) holds 
great promise for the treatment of a wide variety of disorders. To date, the 
predominant use of these vectors has been ex vivo modification of hematopoietic stem 
cells, T cells or other targets where the transduced cell is expected to expand in vivo. For 
example, early clinical trials have shown evidence of disease correction or delay of onset 
in the treatment of thalassemia, adrenoleukodystrophy, chronic lymphocytic leukemia, 
metachromatic leukodystrophy, and Wiskott Aldrich syndrome (Aiuti et al., 2013; Biffi et 
al., 2013; Cartier et al., 2009; Cavazzana-Calvo et al., 2010; Porter, Levine, Kalos, Bagg, & 
June, 2011). These accomplishments would not have been possible without the 
continuous improvements implemented in LV design which have accrued incrementally 
through several generations to help increase the safety and efficacy for their use in 
clinical applications.  
LV are a subclass of retroviral vectors which are derived from the human 
immunodeficiency virus type 1 (HIV-1) lentivirus and have the ability to integrate 
efficiently into quiescent or non-dividing cells (Naldini et al., 1996). As illustrated in 
 2 
 
Figure 1, the wild-type lentivirus has an outer membrane or envelope which consists of 
a lipid bilayer with surface glycoproteins for engaging receptors on its target cells.  
The inside of the virus consists of an inner matrix and a capsid core. Inside of the capsid 
are two copies of a single-stranded viral RNA (vRNA) genome complexed with a 
nucleocapsid for protection from degradation along with the viral proteins necessary for 
maturation, infection and replication. 
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Figure 1. Outline of a wild-type lentivirus. Schematic of a wild-type lentivirus as 
described in the text. GP – surface glycoproteins, Env – envelope or viral membrane, MA 
– inner matrix, NC – nucleocapsid, CA – capsid, PR – protease, IN – integrase, RT – 
reverse transcriptase, vRNA – viral RNA genome.  
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The life-cycle of a lentivirus requires several key steps to maintain an active 
infection (Figure 2). Briefly, (1) the virus first engages receptors on the target cell with 
its surface glycoproteins. This leads to a conformational change of the glycoproteins 
enabling the virus to bind with the cell and fusing their membranes. The contents of the 
virus are released into the cytoplasm after which uncoating of the matrix and inner 
capsid occurs. (2) The single-stranded vRNA is converted to double-stranded DNA using 
the virus reverse transcriptase enzyme and host cell nucleotides. During reverse 
transcription the 3’ LTR is copied to the 5’ end of the viral genome providing identical 
flanking sequences. (3) The double stranded viral DNA and other associated viral 
proteins combine to form a pre-integration complex (PIC) necessary for nuclear import. 
The PIC consists of the reverse transcribed viral cDNA complexed with integrase, matrix, 
reverse transcriptase, and nucleocapsid proteins (Bukrinsky et al., 1993; Farnet & 
Haseltine, 1991b; Fassati & Goff, 2001; M. D. Miller, Farnet, & Bushman, 1997). (4) The 
viral integrase enzyme performs end-processing of the viral DNA, cleaving two 
nucleotides leaving a CA dinucleotide sticky-end and binds to attachment sites at the 
terminal ends of the viral genome. (5) Following nuclear import, integrase then makes a 
staggered cut in the host-cell genome and facilitates strand-transfer and insertion of the 
viral DNA. (6) The integrated viral genome or provirus is then transcribed by host-cell 
machinery to produce viral mRNA which is exported from the nucleus. (7) The viral 
mRNA is then translated by host-cell machinery to produce the components necessary 
for virus production. (8) The virus components along with two copies of the single-
stranded vRNA genome are the transported to the cells plasma membrane where they 
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assemble to form a new virus. (9) An immature virion then buds off of the cells 
membrane which then undergoes additional processing by the protease enzyme to 
produce an infectious mature virion.  
The components necessary to support the viral life-cycle are encoded in the viral 
genome. As illustrated in Figure 3A, the genome of the HIV-1 virus is flanked by two long 
terminal repeats (LTRs) each containing an untranslated 5’ and 3’ segment (U5/U3) 
flanking a repeat region (R) which are necessary for integrase mediated insertion into a 
host genome. The U3 segment contains the promoter elements necessary for 
transcription of the entire proviral genome with preference for initiation at the 5’ LTR 
and the U5 segment providing the polyadenylation signal necessary for termination and 
cleavage at the 3’ LTR (Klaver & Berkhout, 1994). The terminal ends of the 5’ and 3’ LTRs 
in their U3 and U5 segments, respectively, contain DNA attachment sites necessary for 
integrase binding and end-processing. Downstream of the 5’ LTR is a psi or packaging 
sequence (Ψ), which is critical for trafficking of the viral genome to the cell membrane 
for incorporation into viral particles. The backbone of the viral genome codes for the 
proteins necessary for virus formation, replication and infection with three main genes 
gag, pol and env. The gag gene codes for the proteins necessary for the viral structure 
including the inner matrix, capsid, nucleocapsid and other associated proteins (Freed, 
1998). The pol gene codes for the enzymes necessary for replication including reverse 
transcriptase, integrase and protease. The env gene codes for the surface glycoproteins 
necessary for entry to target cells. The native HIV-1 glycoproteins mediate specificity for 
CD4+ cells including T lymphocytes, monocytes, dendritic cells and brain microglia 
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(Wyatt & Sodroski, 1998). In addition to the three main genes, there are two regulatory 
genes, rev and tat. The rev gene codes for the regulator of virion expression protein 
(Rev) which is necessary for export of the viral mRNA from the nucleus via binding to a 
Rev response element (RRE) (Fischer, Huber, Boelens, Mattaj, & Luhrmann, 1995). The 
tat gene codes for the trans-activator of transcription (tat) protein which acts to 
increase provirus transcription necessary for viral replication (Dull et al., 1998). Lastly, 
there are four accessory genes, vif, vpr, vpu, and nef, whose roles are to suppress 
cellular-based restriction and immunity in order to maintain an active infection (Malim 
& Emerman, 2008). 
LV were designed from HIV-1 retaining the ability to enter a target cell, process 
the viral genome, facilitate transport to the nucleus, integrate into the host cell’s DNA, 
and have their transgene of interest transcribed while eliminating their ability to 
replicate which could lead to an active infection. In order to make LV clinically 
applicable, non-essential sequences and genomic regions involved with viral replication 
and virulence were removed from the genome including the accessory proteins, nef, vif, 
vpr, and vpu (Figure 3A). The tat gene was also removed and compensated for by 
placing a constitutively active promoter at the 5’ end of the vector in lieu of the 5’ LTRs 
U3 region for vector production (Dull et al., 1998). The remaining components necessary 
for vector particle production are placed in trans to each other without the packaging 
signal to reduce the risk of recombination and production of a replication competent 
vector. The vector back bone with the flanking LTRs is replaced with a transgene of 
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interest and any necessary promoter or enhancer elements along with the packaging 
signal (Figure 3b). 
Vector particles are generated using a series of plasmids that express the vector 
genome and the viral proteins required for particle formation. The technology for 
packaging vector particles continues to evolve, but the commonly used “third 
generation” systems utilize a series of four vector plasmids that are introduced into cells 
by transient transfection (Figure 3B) (Dull et al., 1998). In addition to the transgene 
plasmid containing the vector backbone or genome, the system uses a plasmid 
expressing the gag and pol gene regions that produce the HIV-1 structural proteins 
required for capsid formation and genome integration.  
A plasmid expressing HIV-1 rev is also included to activate the rev responsive 
element engineered into the transgene and gag/pol plasmids. This facilitates nuclear 
transport and is also included as a safety feature by making it only available during 
production for expression of packaging components (Dull et al., 1998).  
The fourth plasmid expresses the env gene coding for the envelope glycoprotein 
that engages receptors on the target cells. As the native HIV-1 glycoprotein is generally 
restricted to CD4 positive cells, investigators utilize alternative envelopes, most 
commonly the Vesicular Stomatitis Virus G glycoprotein (VSV-G), to facilitate uptake into 
a wide variety of species and cell types (Aiken, 1997).  
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Figure 2. Life cycle of a wild-type lentivirus. A brief overview of the major steps 
involved with infection and replication in the life cycle of a wild-type lentivirus as 
described in the text. 
 
 
 9 
 
Figure 3. Schematic of HIV-1 and Third Generation Lentiviral Packaging System. (A) The 
HIV-1 Virus contains three gene regions gag, pol, and env along with accessory proteins 
and the flanking LTR; (B) The lentiviral components found in the four plasmids used in 
generating third generation lentiviral vectors. The vector plasmid contains a self-
inactivating 3' LTR (SIN-LTR), a Rev responsive element (RRE), a central polypurine tract 
(cPPT), and the Woodchuck Hepatitis Virus Post-Transcriptional Response Element, a psi 
sequence (Ψ) for efficient incorporation of the vector RNA genome into particles, and a 
promoter demonstrated here by the CMV early promoter for transgene expression. The 
packaging plasmid expresses the gag and pol gene regions of HIV-1 which encode 
proteins required for virion formation and vector processing. A plasmid expressing rev is 
provided to facilitate nuclear transport of RRE containing transcripts. The fourth plasmid 
is the envelope plasmid. LV are commonly pseudotyped to increase the range of cell 
types and animal species susceptible to vector transduction. 
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The use of multiple plasmids and the requirement for rev are included to 
minimize recombination events that would lead to the development of a replication 
competent virus. For efficient integration, viral particles must contain the proteins 
encoded in the HIV-1 pol region which are necessary for vector processing including 
reverse transcriptase, integrase and protease. A short portion of gag sequence which is 
critical for generating high titer vector, by contributing to the structure of the packaging 
signal, is also retained in the transgene plasmid (Dull et al., 1998; McBride & 
Panganiban, 1996). The transgene plasmid contains the minimal components of HIV-1 
required for vector production and integration. The transgene of interest is 3' to a 
promoter element that regulates expression. Additional elements are added to increase 
vector production and/or expression including a polypurine tract (PPT) (Barry et al., 
2001; Van Maele, De Rijck, De Clercq, & Debyser, 2003) and the Woodchuck Hepatitis 
Virus Post-Transcriptional Response Element (WPRE) (Dupuy et al., 2005; Zufferey, 
Donello, Trono, & Hope, 1999).  
An important safety feature of most LVs is the inclusion of a Self-Inactivating 
Long Terminal Repeat (SIN-LTR). This feature minimizes the risk of producing a 
replication-competent lentivirus by recombination with wild-type viruses. The 
mechanism involves taking advantage of the normal replication cycle of HIV-1. In wild-
type HIV-1, the viral promoter is within the U3 region of the 5' LTR and is required to 
generate the full length viral transcript. The U3 region is also present in the 3' LTR but is 
not essential in the DNA form of the virus. During viral replication, the RNA genome is 
reverse transcribed and the 3' LTR is utilized in formation of both the 5' and 3' LTR of the 
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daughter virus. By incorporating a large deletion including the promoter elements into 
the U3 region of the 3' LTR any progeny will contain two inactivated LTR after reverse 
transcription (Miyoshi, Blomer, Takahashi, Gage, & Verma, 1998; Zufferey et al., 1998). 
Transgene expression is then dependent solely on the internal promoter (for example, 
the CMV promoter engineered into the vector plasmid as illustrated in Figure 3B).  
Another safety element included in the design of lentiviral vectors is the use of 
insulator elements. Insulator elements reduce the chance of vector induced activation 
of genes near insertion sites by shielding the transduced genome from enhancers 
included in vector design and incomplete vector termination reading through into the 
genome (Ramezani, Hawley, & Hawley, 2008) 
LVs are generated by introducing the transgene and packaging plasmids into 
producer cells, most commonly HEK 293T cells (Figure 4). Vector supernatant is 
collected from the media and typically contains between 105 and 107 infectious units 
per milliliter. This is dependent on the vector design as the addition or deletion of 
elements to vector design can affect vector titer. After collection vector supernatant is 
DNase treated to remove any residual plasmid DNA prior to downstream processing 
(Sastry, Xu, Cooper, Pollok, & Cornetta, 2004). The removal of plasmid DNA is essential 
to prevent exposing LV treated patients to HIV-1, which could pose the risk of 
recombination with endogenous retroviral sequences resulting in a replication 
competent lentiviral vector. LV can be concentrated by ultracentrifugation and clinical 
vector products are usually purified using a combination of chromatography, tangential 
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flow filtration and diafiltration (Leath & Cornetta, 2012; Merten et al., 2011; Slepushkin 
et al., 2003). 
In addition to the development of integrating LV, investigators have also sought 
to develop non-integrating lentiviral vectors (NILV) for applications where integration is 
not necessary or warranted. Similar to other non-integrating vectors, such as adenoviral 
vectors and adeno-associated viruses, NILV express their genome episomally as either 
the linear transcript product from the reverse transcribed vRNA, a 1-LTR circle formed 
through homologous recombination of the vectors LTRS, or a 2-LTR circle formed 
through non-homologous end-joining at the terminal ends of the LTRs. In order to 
effectively transduce a target cell, both integrating LV and NILV must retain the ability to 
readily enter the cell, form a pre-integration complex, be transported into the nucleus 
and efficiently express its genetic payload. Depending on the envelope pseudotype used 
the membrane bound LV particles enter cells either by direct fusion with the plasma 
membrane (Clapham & McKnight, 2002) or via a receptor-mediated endosomal pathway 
(Aiken, 1997). In the direct fusion pathway the LV is uncoated upon entry to release the 
viral contents into the cytoplasm. This allows for reverse transcription of the viral RNA 
into linear cDNA and development of the pre-integration complex (PIC). The endosomal 
pathway is dependent upon the pH within the endosome for membrane fusion, 
subsequent uncoating, and PIC formation within the cytoplasm. The transportation of 
the PIC to the nucleus is not completely understood, but is believed to occur by an ATP-
dependent process (Bukrinsky et al., 1992) via nucleoporins (De Rijck, Vandekerckhove, 
Christ, & Debyser, 2007; Stevenson, 1996) using nuclear localization signals and cellular 
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transport mechanisms (Fassati, 2006). Certain of the known localization signals have 
been removed during LV design; nevertheless, the transduction of quiescent cells by LV 
is well documented.  
Understanding the processing of the LV cDNA after reverse transcription is 
important when designing NILV. Normally the linear LV cDNA generated during reverse 
transcription enters the nucleus with the linear 2-LTR form (Chun et al., 1997) 
representing the preferred substrate for integration (Folger, Wong, Wahl, & Capecchi, 
1982; L. Li et al., 2001). A small portion of LV genomes can persist episomally as linear 
cDNA, 2-LTR circular forms or 1-LTR circular forms. The majority of 2-LTR circles are 
formed through non-homologous end-joining (NHEJ) of the 5' and 3' LTRs (Jeanson et 
al., 2002; Kilzer et al., 2003; L. Li et al., 2001). The majority of 1-LTR circles are formed by 
homologous recombination (HR) between the LTRs (Farnet & Haseltine, 1991a; Gianni, 
Smotkin, & Weinberg, 1975; Gilboa, Mitra, Goff, & Baltimore, 1979; Jacque & 
Stevenson, 2006; Kilzer et al., 2003; Shank et al., 1978), as an aberrant product of 
incomplete reverse transcription (Dina & Benz, 1980; Junghans, Boone, & Skalka, 1982; 
Kantor et al., 2011; Klarmann, Yu, Chen, Dougherty, & Preston, 1997; Ringold, 
Yamamoto, Shank, & Varmus, 1977), or through alternative mechanisms such as 
autointegration (Shoemaker et al., 1980). It is these episomal forms that allow for the 
stable expression of the vector transgene without integration in non-dividing cells 
(Apolonia et al., 2007; Bayer et al., 2008; Philippe et al., 2006; Rahim et al., 2009).  
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Figure 4. Generation of Lentiviral Vector by Transient Transfection. The four packaging 
plasmids are transfected into cells that have a high capacity for vector production. The 
most commonly used cell line is HEK 293T. Maximal vector production occurs 48–72 h 
after transfection. The vector particles are released into the media which is collected 
and clarified of cell debris. Vector particles can be further purified and/or concentrated. 
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B. Development of non-integrating lentiviral vectors 
“Adapted from Shaw A, Cornetta K. Design and Potential of Non-Integrating Lentiviral 
Vectors. Biomedicines. 2014; 2(1):14-35” 
 
When designing NILV it is important that modifications maintain the vectors 
ability to enter their target cells, perform reverse transcription, transport the PIC into 
the nucleus and efficiently express their transgene product. This entails selectively 
inhibiting or altering only the aspects of the vectors lifecycle that lead to integration. As 
integrase-mediated catalysis is the primary means of integration for LV, the inhibition of 
its function is necessary in the development of NILV. 
In wild-type lentiviral vectors integration into the target cell’s genome is 
mediated by the viral integrase. This protein first binds to the viral cDNA at attachment 
sites located within the U3 region of the 5' LTR and the U5 region of the 3' LTR 
(Hindmarsh & Leis, 1999; Kulkosky & Skalka, 1994; Masuda, Kuroda, & Harada, 1998; H. 
Zhou, Rainey, Wong, & Coffin, 2001). Integrase processes the 3' ends of the viral cDNA 
leaving a CA dinucleotide overhang (Craigie, Fujiwara, & Bushman, 1990; Katz, Merkel, 
Kulkosky, Leis, & Skalka, 1990) and then attaches the recessed ends to the 5' 
phosphorylated ends of a double-stranded cut made in the target genome. Integrase 
then repairs the gaps resulting in a 5 base-pair repeat flanking the inserted vector 
genome (Katz et al., 1990; Mizuuchi, 1992). There are three general points that can be 
targeted in developing a NILV; mutations in the integrase protein that alter its ability to 
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process the target cell chromosomal DNA or alteration in the vectors 5’ or 3’ LTR 
attachment sites that prevent integrase from binding and facilitating integration. 
The most common target for inhibiting viral integration is mutation of the 
integrase protein, producing integrase-defective lentiviral vectors. LV integrase is coded 
for by the HIV-1 Pol region and the region cannot be deleted as it encodes other critical 
activities including reverse transcription, nuclear import, and viral particle assembly 
(Gallay, Hope, Chin, & Trono, 1997; Zhu, Dobard, & Chow, 2004). Mutations in pol that 
alter the integrase protein fall into one of two classes: those which selectively affect 
only integrase activity (Class I); or those that have pleiotropic effects (Class II) 
(Engelman, 1999). Mutations throughout the N and C terminals and the catalytic core 
region of the integrase protein generate Class II mutations that affect multiple functions 
including particle formation and reverse transcription (Engelman, 1999; Saenz et al., 
2004; Wiskerchen & Muesing, 1995). Therefore, class II mutations are not suitable when 
designing NILVs because they disrupt functions that are critical for vector processing and 
expression.  
Class I mutations limit their effect to the catalytic activities, DNA binding, linear 
episome processing and multimerization of integrase (Banasik & McCray, 2010). The 
most common Class I mutation sites are a triad of residues at the catalytic core of 
integrase, including D64, D116, and E152 (Kulkosky, Jones, Katz, Mack, & Skalka, 1992; 
Shibagaki & Chow, 1997). Each mutation has been shown to efficiently inhibit 
integration with a frequency of integration up to four logs below that of normal 
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integrating vectors while maintaining transgene expression of the NILV (Apolonia et al., 
2007; Leavitt, Robles, Alesandro, & Varmus, 1996; Nightingale et al., 2006). 
Another alternative method for inhibiting integration is mutations in the 
integrase DNA attachment sites (LTR att sites) within a 12 base-pair site of the U3 or an 
11 base-pair site of the U5 regions at the terminal ends of the 5' and 3' LTRs, 
respectively (Apolonia et al., 2007; Brown, Chen, & Engelman, 1999; Masuda et al., 
1998; Masuda, Planelles, Krogstad, & Chen, 1995; Nightingale et al., 2006). These 
sequences include the conserved terminal CA dinucleotide which is exposed following 
integrase-mediated end-processing. Single or double mutations at the conserved CA/TG 
dinucleotide result in up to a three to four log reduction in integration frequency 
(Nightingale et al., 2006); however, the vector retains all other necessary functions for 
efficient uptake and expression. 
While NILV can significantly reduce the frequency of integration there still 
remains a low level of vector integration (Apolonia et al., 2007; Cornu & Cathomen, 
2007; Gaur & Leavitt, 1998; Leavitt et al., 1996; Leavitt, Shiue, & Varmus, 1993; Matrai, 
Chuah, & VandenDriessche, 2010; Nakajima, Lu, & Engelman, 2001; Nightingale et al., 
2006; Philippe et al., 2006; Yanez-Munoz et al., 2006). Integration associated with NILV 
has been studied using insertion site analysis and high-throughput sequencing. These 
analyses indicate that the integration observed is not integrase-mediated as the 
insertion sites lack the canonical features of LTR end-processing including the five base-
pair repeat of genomic DNA flanking at the site of vector insertion (Gaur & Leavitt, 1998; 
Koyama, Sun, Tokunaga, Tatsumi, & Ishizaka, 2013; Matrai et al., 2011; Matrai et al., 
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2010; Nightingale et al., 2006). The vector inserts also vary with some containing fully 
intact sequence, truncations at the terminal ends of the LTRs, or insertions/deletions of 
genomic DNA flanking the vector. A significant number of these integrations are 
occurring at sites of chromosomal breakage and are mediated by NHEJ mechanisms 
(Koyama et al., 2013; D. G. Miller, Petek, & Russell, 2004). It may be possible to impede 
illegitimate integration of NILV by inhibition of cellular factors in the double-strand 
break (DSB) repair pathway (Koyama et al., 2013). Whether or not inhibitors to DNA 
repair can be used clinically to limit non-integrase mediated integration remains to be 
determined.  
Another method for further reducing the frequency of illegitimate integration is 
limiting the linear form of the vector DNA. Linear DNA has been shown to integrate 
much more efficiently than supercoiled DNA associated with circular DNA (Folger et al., 
1982; L. Li et al., 2001). The linear form also appears to be the preferred substrate for 
both integrase and non-integrase-mediated insertion. One approach has been to limit 
linear 2-LTR episomal forms by inducing the formation of circular episomal forms. For 
example, Kantor and colleagues have shown that deleting the vectors 3' polypurine tract 
(PPT) results in aberrant reverse transcription leading to the preferential formation of 1-
LTR circular episomes and a reduction in linear forms (Kantor et al., 2011). Using this 
strategy they were able to reduce the frequency of integration by 10-fold when using an 
integrating vector. Of relevance to NILV, this modification reduced the frequency of 
integration of an integrase deficient LV by another 3-fold over integrase deficient LV 
without the modification. As newer modifications are developed to reduce integration 
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they will need to be tested experimentally to ensure there is no reduction in the level of 
transgene expression. 
It should be noted that LTR att site mutations have been directly compared to 
point mutations in integrase. The consensus is that mutations to integrase provide a 
greater reduction in the frequency of integration. Yanez-Munoz et al. estimated the 
frequency of reversion mutations in NILV to reach 1/815 (Yanez-Munoz et al., 2006). The 
point mutations to LTR att sites could carry a higher rate of reversions but whether LTR 
att site mutations with larger deletions will reduce the frequency of illegitimate 
integration remains to be determined. Interestingly, while mutations to integrase and 
the LTR att sites independently inhibit integration efficiently, some studies suggest there 
are no synergistic effects upon combining these mutations to further reduce integration 
by a vector (Apolonia et al., 2007; Nightingale et al., 2006). However, whether this is due 
to the type or efficiency of the mutations being combined remains to be determined.  
While NILV can effectively inhibit integration, they are associated with a 
significantly reduced level of transgene expression as compared to a normal integrating 
LV (Apolonia et al., 2007; Bayer et al., 2008; Cornu & Cathomen, 2007; Coutant, Frenkiel, 
Despres, & Charneau, 2008; Kantor et al., 2011; Nakajima et al., 2001; Naldini et al., 
1996; Philippe et al., 2006; Vargas, Gusella, Najfeld, Klotman, & Cara, 2004; Vargas, 
Klotman, & Cara, 2008). This remains a key issue in developing clinically effective NILV. 
One approach for improvement is removing or reducing inhibitors to episomal 
transgene expression. Bayer et al. have shown that removal of cis-acting sequences 
within the U3 region of the vectors LTR improves episomal transgene expression by 
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nearly 3-fold (Bayer et al., 2008). However, other mechanisms of episomal inhibition 
may be involved because expression was still below that of the normal, integrating LV 
control.  
Other approaches include the inhibition of cellular restriction factors (Berger, 
Goujon, Darlix, & Cimarelli, 2009; Negri et al., 2012), codon optimization to improve 
protein production and potency (Negri et al., 2007; Suwanmanee et al., 2013), and the 
use of histone deacetylase inhibitors for transgene activation (Pelascini, Janssen, & 
Goncalves, 2013). 
Combining modifications that increase transgene expression and reduce 
integration will be needed to maximize the safety profile of NILV. If expression is low, a 
higher number of NILV will be required per cell to obtain the therapeutic benefit. The 
higher numbers of vector episomes will in turn increase the chance of illegitimate 
integration. For certain gene therapy trials, such as those using ex vivo gene transfer of 
CD34+ hematopoietic cells, the number of cells treated may exceed 5 × 108 cells for an 
adult. Even with a four log reduction in integration, a significant number of cells will 
contain integrated proviruses. Therefore efforts to minimize integration and optimizing 
expression should be considered for both therapeutic and safety reasons. 
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C. Insertion site analysis 
 
A hallmark of LV is their ability to stably integrate their genome into a host cell’s 
DNA. Integrase mediated insertion by LV while theoretically random in nature, 
demonstrates preferential insertion in gene coding regions (Schroder et al., 2002). This 
presents the risk of insertional mutagenesis which could lead to aberrant gene 
expression and possible oncogenesis. Site-directed integration systems can offer a safer 
alternative to integrase-mediated insertion, though they have demonstrated some off-
target insertions which must be accounted for to improve their clinical utility (Beumer, 
Bhattacharyya, Bibikova, Trautman, & Carroll, 2006; J. C. Miller et al., 2007). Several 
methods have been employed for the analysis of insertion sites of wild-type LV, 
however NILV offer more difficulty in their capture and analysis. Whereas wild-type LV 
insert by integrase-mediated integration with intact vector sequences and canonical 
features including end-processing and a five base-pair flanking repeat, NILV insertions 
are much more variable. NILV have been shown to integrate by non-integrase-mediated 
mechanisms such as HR and/or NHEJ (Gaur & Leavitt, 1998; Matrai et al., 2011; 
Nightingale et al., 2006). NILV insertion sites present insertions and/or deletions at the 
vector-genome junction which could inhibit many of the PCR-based methods for vector 
insertion site analysis, which are dependent on intact primer sites located at or near 
these junctions. In order to develop vectors with safer insertion site profiles and to 
evaluate the integrity of insertion sites post-transduction, it is necessary to have 
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methods in place which can evaluate them with a high degree of sensitivity and in a 
high-throughput manner while accounting for variables in the vector-genome junction. 
Previous techniques for the capture of vector integration sites were either very 
labor intensive and/or lacked the sensitivity necessary to evaluate the large number of 
insertion sites possible in many applications. One technique which has been applied that 
can effectively evaluate the variable insertion sites of NILV employs the use of inverse 
PCR followed by insertion of the PCR product into cloning vectors (Nightingale et al., 
2006). However this type of technique is very labor intensive and limits the number of 
insertion sites which can be analyzed in a high throughput manner. Another method 
that has been utilized for capturing vector insertion sites is ligation-mediated PCR (LM-
PCR) (Mueller & Wold, 1989). However this method lacks the sensitivity to capture a 
large number of integrations or characterize the variability associated with NILV 
insertion sites. Two of the most sensitive methods for analyzing vector insertion sites 
are linear amplification-mediated PCR (LAM-PCR) (Schmidt et al., 2007) and 
nonrestrictive LAM-PCR (nrLAM-PCR) (Gabriel et al., 2009). These methodologies have 
been combined with next-generation sequencing to successfully analyze large numbers 
of insertion sites in a relatively high-throughput manner. However, these methods have 
their limitations as well. LAM-PCR utilizes restriction enzymes and is therefore 
dependent on the presence of restriction sites in proximity to the vector insertion site 
and can result in missing up to 50% of insertion sites (Gabriel et al., 2009). A major 
hurdle with nrLAM-PCR is the necessity for a single stranded ligation of a linker cassette. 
The technology available for this step is very inefficient as most enzymes with this 
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capability are intended for use with single-stranded RNA templates. An important 
obstacle with both of these methods for the elucidation of NILV insertion sites is the 
necessity for LTR-specific primers to amplify the vector-genome junction. Deletions at 
the vector-genome junction are common with NILV which could result in the loss of 
retrieving these insertion sites depending on the size of the deletion. As new 
technologies have emerged, improved methodologies have been developed for 
analyzing vector insertion sites that can bypass many of these limitations. These 
techniques utilize sonication to shear the vector transduced DNA to fragments in a size 
range which allows for easier manipulation and analysis. Some methods which utilize 
this technique still rely on the use of LTR-specific primers for the capture, purification 
and analysis of insertion sites (De Ravin et al., 2014; S. Zhou et al., 2014). However, 
utilizing on optimal sheared fragment size and modifying the primer site to sit farther 
back within the vector can allow for capture of a larger percentage of NILV insertion 
sites which contain deletions at the vector-genome junction. As high-throughput next 
generation sequencing technologies advance and allow for the processing of larger 
templates the analysis of insertion sites without the necessity to depend on primer or 
restriction sites will allow a more accurate evaluation which can improve the safety of 
these vectors for use in the clinic. 
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D. Statement of Purpose 
  
 The inherent risks associated with using viral vectors in patients along with 
adverse side effects observed with early retroviral vector trials necessitates the 
continuous improvement of lentiviral vector mediated gene therapy to facilitate its 
safety for use in the clinic. We have evaluated modifications in vector production to 
improve the purity of the vector supernatant, designed novel non-integrating lentiviral 
vectors with multiple modifications to vector design, and optimized methodologies for 
analyzing vector insertion sites post-transduction. We hypothesized that by utilizing the 
results from these studies we can improve the safety of lentiviral vector mediated gene 
therapy by incorporating more clinically relevant reagents into vector production, 
developing NILV with reduced frequencies of illegitimate integration, and improving our 
ability to analyze the aberrant insertion sites associated with NILV. This was 
accomplished through the following specific aims: 
 
1. Improving the purity of lentiviral vector supernatant through incorporation of an FDA 
approved deoxyribonuclease (DNase) into vector production.  
 This aim will test the hypothesis that incorporating an FDA approved 
recombinant human DNase into lentiviral vector production for removing residual 
plasmid DNA will improve the purity and clinical potential of the final vector 
supernatant product. By applying quantitative PCR (Q-PCR) we will determine whether a 
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DNase, FDA approved for use in treating patients with cystic fibrosis, will provide a more 
clinically relevant alternative to a previously described bacterial-derived DNase. 
 
2. Combining multiple modifications to NILV design to improve their safety and efficacy 
for clinical applications. 
 By using flow cytometry, an antibiotic resistant colony formation titer assay, 
and Q-PCR copy number analysis, the aim will demonstrate that novel NILV combining 
multiple modifications for inhibiting vector integration and a deletion mutation for 
improving transgene expression results in NILV backbones with safer profiles for use in 
applications where integration is not necessary.   
 
3. Modifying vector insertion site capture methodologies to improve the analysis of 
aberrant NILV insertion sites. 
 By utilizing optimized vector insertion site capture methodologies coupled 
with high-throughput next-generation sequencing, this aim will improve the ability to 
analyze the integration profiles of vectors while taking into account the aberrant vector-
genome junctions associated with NILV. 
 
 The following chapters within this dissertation describe the methods and 
results of these specific aims. 
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II. Using Pulmozyme DNase treatment in lentiviral vector production 
“Reprinted with permission from HUMAN GENE THERAPY: METHODS 2012, published by 
Mary Ann Liebert, Inc., New Rochelle, NY” 
 
A. Introduction 
 
 Lentiviral vectors have shown promise as a new therapeutic tool for patients 
with life threatening disorders (Cartier et al., 2009; Cavazzana-Calvo et al., 2010; 
DiGiusto et al., 2010; Kalos et al., 2011; Levine et al., 2006). Most investigators 
generating lentiviral vectors utilize a transient transfection when manufacturing these 
vectors for research and clinical applications (Dull et al., 1998; Gasmi et al., 1999; X. Lu 
et al., 2004). Vector components are separated into different plasmids to reduce the risk 
of recombination and the potential production of a replication competent lentivirus 
(RCL) (Dull et al., 1998; Zufferey et al., 1998), a strategy that to date appears effective 
(Cornetta et al., 2011). A concern with the transient transfection method is the residual 
plasmid DNA remaining in the final product, potentially exposing patients to plasmids 
expressing HIV-1 DNA (Zufferey, 2002). To decrease this risk, the DNase Benzonase has 
been shown to significantly decrease plasmid DNA in lentiviral vector preparations 
(Sastry et al., 2004). Unfortunately, Benzonase is a bacterial derived product and does 
not have FDA approval, a factor that will be problematic as vectors move from early 
phase studies into licensed products. In contrast, Pulmozyme is a recombinant human 
DNase (rhDNase) that is FDA approved for the treatment of cystic fibrosis (Pan, 
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Sinicropi, & Lazarus, 2001; Shak, Capon, Hellmiss, Marsters, & Baker, 1990; Shire, 1996; 
Ulmer et al., 1996) and could serve as a safer alternative.  
 The timing of DNase treatment is also an area for potential improvement. 
DNase is generally added to the vector product after the final harvest, increasing 
processing time that can decrease the potency of the final product. Moreover, the 
DNase will remain in the final product unless additional processing is performed.  We 
therefore compared DNase treatment of the final product versus adding DNase earlier 
in the production process as a potential means to minimize residual DNase in the final 
product. Our findings demonstrate that Pulmozyme is an effective DNase and a suitable 
alternative to Benzonase for removing plasmid DNA from lentiviral vector products. 
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B. Methods 
 
Cell culture and reagents 
 HEK293T cell lines were used for vector production and HEK293 cells were 
used for transduction and subsequent infectious titer measurement. Both cell lines were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA) and were 
maintained in D10 medium [88% high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen, Carlsbad, CA), 10% fetal bovine serum (FBS, HyClone, Logan UT), 
100 units/ml penicillin-streptomycin (Pen Strep, Invitrogen) and 2 mM Glutamax 
(Invitrogen)] incubated at 37°C with 5% CO2. Viral supernatants were harvested in 
OptiPRO Serum Free Medium (Invitrogen). 
 
Vector production  
 Vector was generated in HEK 293T cells plated at 2 X 106 / T25 flask in D10 
medium. After approximately 24 hours the medium was changed to fresh D10 with the 
subsequent addition of the transfection mixture using the Promega Profection 
mammalian transfection kit (Promega, Madison, WI) according to the manufacturer’s 
instructions. The transgene vector plasmid used was pcDNA-CS-CGW (4.4 µg/T25 flask) 
provided by Philip Zoltick (Children’s Hospital, Philadelphia, PA), containing the 
enhanced green fluorescent protein (eGFP) gene driven by the cytomegalovirus (CMV) 
promoter. The three packaging plasmids used were pMDL expressing gag-pol (2.2 
µg/T25 flask), pMDG expressing the vesicular stomatitis virus (VSV)-G envelope 
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glycoprotein (1.5 µg/T25 flask) and pRSV-REV for Rev expression (1.1 µg/T25 flask) (Dull 
et al., 1998; Zufferey et al., 1998). The cells were then incubated at 37° C for 16 – 18 
hours after which time the transfection medium was replaced with OptiPRO serum-free 
medium. Twenty four hours later the viral supernatant was collected and clarified using 
a 0.45 µm filter and stored at -80° C.  
 
DNase treatment 
 Enzymes used for plasmid DNA removal were Benzonase nuclease (Novagen, 
Darmstadt Germany), and pharmaceutical grade Pulmozyme (Dornase alpha; 
Genentech, Inc., San Francisco, CA). DNase treatment was tested at two time points 
(Figure 5). In Protocol A DNase is added to the final product after vector harvest and 
clarification. In Protocol B, DNase treatment was added at the end of an 18 hour 
transfection and immediately prior to the final medium change. Vector was incubated 
with the DNase at 37° C with 5% CO2. The incubation times and DNase concentrations 
for both protocols are described in Results. 
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Figure 5. Protocols for DNase treatment during lentiviral vector production. 
(A) Protocol A illustrates that DNase is added to harvested vector at the end of 
production. (B) Protocol B illustrates the addition of DNase at the end of the 
transfection period and prior to medium change and subsequent harvest. 
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Residual DNA purification 
 DNA was extracted by a phenol/chloroform purification followed by ethanol 
precipitation in order to completely deactivate any residual DNase. An equal volume of 
phenol:choloroform:isoamyl alcohol (25:24:1; Sigma-Aldrich, St. Louis, MO) was added 
to the viral supernatant. The mixture was then vortexed and spun for 10 minutes at 
13,000 RPM. The aqueous phase was removed and an equal volume of 
chloroform:isoamyl alcohol 24:1 (Sigma-Aldrich, St. Louis, MO) was added. The tube was 
briefly vortexed and spun for 10 minutes at 13,000 rpm. The aqueous phase was 
removed and adjusted to 0.3M sodium acetate. Twice the volume of ice-cold 100% 
ethanol was added and incubated at -80° C for two hours followed by to centrifugation 
at 4° C for 30 minutes. The pellet was washed with 70% ethanol, centrifuged at 4° C for 
30 minutes, air dried, then resuspended in water at 65° C for one hour. The DNA 
concentration was obtained using the NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE) or with a BioPhotometer (Eppendorf, Hamburg, 
Germany). 
 
Real Time PCR 
 Quantitative-polymerase chain reaction (Q-PCR) was performed with the 
7500 Real- Time PCR System and analyzed using its 7500 system SDS software (Applied 
Biosystems, Life Technologies Corporation, Carlsbad, CA). Q-PCR was performed with 
forward and reverse primers (VSVG-F1: 5’-tgcaaggaaagcattgaacaa-3’ and VSVG-R1: 5’-
gaggagtcacctggacaatcact-3’) and a probe specific for a 120 bp fragment of the VSV-G 
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envelope sequence (TP-VSVG: 5’-6FAM-aggaacttggctgaatccaggcttcc-TAMRA-3’). Purified 
plasmid DNA was normalized based on the volume of the supernatant tested by diluting 
equally to within an optimal range for working concentrations. 2 µl of the normalized 
plasmid DNA was added to a PCR master  mix consisting of 1X Taqman Buffer A, 0.4 mM 
dNTPs, 1 mM MgCl2, 1.2 µM VSVG-F1 & VSVG-R1 primers, 0.4 µM TP-VSVG probe and 
0.025 U/µl AmpliTaq Gold. Reactions were performed in duplicate or triplicate using one 
cycle of 50° C for 2 min., 95° C for 10 min. and 40 cycles of 95° C for 15 sec. and 60° C for 
1 min. A standard curve was prepared on the basis of serial dilutions of a VSVG standard 
ranging from 101 to 105 copies. 
 
Measurement of infectious titer 
 Determination of infectious titer was performed in order to determine the 
effect of DNase treatment on vector titer. HEK293 cells were transduced in duplicate by 
plating cells at 105 cells per well in six well tissue culture treated plates and incubated 
overnight at 37°C with 5% CO2. The next day the medium was removed and a 
transduction mix (D10 culture medium, 8 μg/ml of polybrene (Sigma-Aldrich), and serial 
dilutions of 1:100 and 1:1000 of viral supernatant) was added and then returned to the 
incubator for four hours.  The transduction mix was then removed and two ml of fresh 
culture medium was added and the cells were incubated for approximately 72 hours. 
Cells were trypsinized, washed in Dulbecco’s Phosphate Buffered Saline (DPBS, 
Invitrogen), pelleted and resuspended in 250 μl of 1% paraformaldehyde in DPBS. In 
order to calculate infectious titer, GFP expression was measured using a FACScan 
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(Becton Dickinson Immunocytometry Systems, San Jose, CA) as previously described 
(Sastry, Johnson, Hobson, Smucker, & Cornetta, 2002). 
 
Analyzing plasmid DNA degradation in serum 
 DNA for the RD114 envelope plasmid was utilized to analyze the effects of 
serum and calcium phosphate on DNA degradation. RD114 Plasmid (50 ng/µl) was 
incubated at 37°C with 5% CO2 in serum free DMEM medium, D10, or complexed with 
the calcium phosphate mix as described above added to D10 medium. Various 
incubation times up to four hours were observed. After incubation, 5 mM EDTA was 
added to inhibit any DNase activity and the results were compared by running the 
products on an agarose gel. 
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C. Results 
 
 The ability of Pulmozyme to decrease plasmid DNA in lentiviral supernatant 
was assessed by generating third generation lentiviral vectors using a four plasmid 
system, including plasmids expressing gag/pol, Rev, the VSV-G envelope, and a 
transgene plasmid expressing GFP. Vector was generated using calcium phosphate 
transfection, and DNase treatment of the final product was compared to DNase 
treatment at the end of the transfection (Figure 5). Plasmid removal was assessed by Q-
PCR with primers specific for the VSV-G envelope gene (the VSV-G plasmid represents 
approximately 1/8th of the total transfected DNA).  As a control, 50 U/ml of Benzonase 
was utilized, as this concentration of DNase has previously been shown to efficiently 
remove plasmid DNA from lentiviral products (Sastry et al., 2004).  
 
DNA Degradation after Treatment with Pulmozyme® 
 The degradation of plasmid DNA after vector harvest (Protocol A, Figure 5) 
was evaluated using a variety of Pulmozyme concentrations ranging from 1 to 50 U/ml. 
Benzonase, at 50 U/ml, was used as a control. Incubation time was one hour. As shown 
in Figure 6, concentrations of Pulmozyme at or above 20 U/ml decreased plasmid DNA 
to within the limits of detection, and plasmid DNA removal by Pulmozyme was equal to 
or better than the removal obtained with Benzonase. Increasing the incubation time to 
two or four hours did not improve DNA degradation when treating by this method (data 
not shown).  
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 Next, the efficiency of DNA degradation was measured when DNase was 
added at the end of the transfection period and prior to the final medium change 
(Protocol B, Figure 5). As shown in Figure 7A, Pulmozyme at a concentration of 25 U/ml 
provided a greater than two log decrease in plasmid DNA and was comparable to or 
better than 50 U/ml of Benzonase. Increasing the Pulmozyme concentration above 25 
U/ml did not provided any added benefit (Figure 7A). Concentrations less than 25 U/ml 
did not attain a two log reduction (data not shown). Any potential adverse effect of 
Pulmozyme on vector titer was also assessed. As shown in Figure 7B, the vector titer 
was not significantly affected by Pulmozyme, even at concentrations up to 100 U/ml. 
 To determine whether longer incubation times following protocol B would 
improve the effectiveness of Pulmozyme, the incubation time at the end of the 
transfection period was increased. As shown in Figure 8A, addition of Pulmozyme at 25 
U/ml led a similar amount of residual DNA in the final product after 1, 2, and 4 hours of 
incubation. To evaluate whether longer incubations allowed for a decrease in 
Pulmozyme concentrations, a four hour incubation was performed with concentrations 
varying from 5 to 25 U/ml. As shown in Figure 8B, the lowest DNA content was noted at 
20 and 25 U/ml. The 4-hr incubation did not alter the vector titer (Figure 8C). When 
taking the data in aggregate, adding Pulmozyme at 20 U/ml after transfection and 
incubating for one hour gave optimal DNA degradation, and results were similar to or 
better than with Benzonase at 50 U/ml. Unfortunately, the level of DNA degradation 
when treating after transfection (protocol B) was significantly less than that obtained by 
treating after vector harvest (protocol A). 
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DNA degradation in the presence of serum 
 A significant difference between the vectors treated in protocol A versus the 
vector treated in protocol B is the presence of serum in the medium. Specifically, in 
protocol A the vector is treated in serum-free medium, whereas the vector in protocol B 
is treated in serum-containing medium. To evaluate the effectiveness of DNase in the 
different media we incubated plasmid DNA in serum-free medium (OptiPRO), and in D10 
medium (DMEM with 10% fetal bovine serum), for up to 4 hours (37°C, 5% CO2). 
Interestingly, free plasmid DNA is stable in serum-free medium (Figure 9A), whereas 
plasmid in medium containing fetal bovine serum leads to a time-dependent 
degradation of plasmid DNA (Figure 9B). Complexing plasmid DNA with calcium 
phosphate provides some protection from serum degradation (Figure 9C). This is 
consistent with observations that calcium phosphate can form complexes with DNA that 
are resistant to extracellular DNase activity (Loyter, Scangos, & Ruddle, 1982). However, 
complexing plasmid DNA with calcium phosphate does not appear to provide the same 
degree of protection in the presence of Pulmozyme (Figure 9D). These findings suggest 
that the lower DNA degradation seen with protocol B is not the result of Pulmozyme 
inhibition by serum. 
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Figure 6. Plasmid DNA degradation after 1 hour of DNase treatment post-harvest. 
Average Q-PCR results from four experiments using primers for the VSV-G plasmid as a 
measure of residual plasmid DNA after DNase treatments. X-axis values represent the 
Unit/ml of DNase for Pulmozyme [P], Benzonase [B] or an untreated control [Un]. Values 
on the Y-axis represent the number of gene copies per 500 µl of viral supernatant. Error 
bars indicate the standard deviation (SD) of the mean. 
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Figure 7. Plasmid DNA degradation after 1 hour DNase treatment performed at the 
end of transfection. (A) Average Q-PCR results for duplicate experiments using primers 
for the VSV-G plasmid as a measure of residual plasmid DNA in the final product. DNase 
treatment was performed at the end of transfection. X-axis values represent the Unit/ml 
of DNase for Pulmozyme [P], Benzonase [B] or an untreated control [Un]. Values on the 
Y-axis represent the number of gene copies per 500 µl of viral supernatant. (B) 
Infectious titer of final vector product as assessed by GFP expression, given as infectious 
units per ml. Error bars represent SD of the mean. 
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Figure 8. Plasmid DNA degradation over time when treating at the end of transfection.  
(A) Q-PCR results for VSV-G plasmid in the final product when Pulmozyme (25 U/ml) is 
added at the end of transfection for 1-4 hours. Values on the Y-axis represent the 
number of gene copies per 500 µl of viral supernatant. (B) Q-PCR results of residual VSV-
G after a 4 hour incubation with various concentrations of DNase. X-axis values 
represent the U/ml of DNase for Pulmozyme [P], Benzonase [B] or an untreated control 
[B]. Values on the Y-axis represent the number of gene copies per 500 µl of viral 
supernatant. (C) Infectious titer of final vector product as assessed by GFP expression, 
given as infectious units per ml. Error bars represent SD of the mean. 
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Figure 9. The effects of serum and calcium phosphate on plasmid DNA degradation. 
Plasmid incubated in (A) serum free medium (OptiPRO); (B) D10 (serum containing) 
medium; (C) plasmid complexed with calcium phosphate incubated in D10 medium; and 
(D) plasmid complexed with calcium phosphate incubated in D10 medium with 25 U/mL 
of Pulmozyme. Each sample began with 50 ng/µL of RD114 plasmid and was analyzed on 
a 1.2% TAE gel. 
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Cost Analysis 
 Another consideration when assessing the feasibility of replacing Benzonase 
with Pulmozyme is the cost. Currently, the cost of Benzonase is $6.60 per 1000 units 
compared to $26.80 for 1000 units of Pulmozyme. For treating 20 liters of 
unconcentrated product, the cost of Benzonase (50 U/ml) is estimated at $6,600 while 
the cost of Pulmozyme (20 U/ml) is estimated at $10,720. To decrease costs, we 
currently concentrate vector product 10-fold prior to DNase treatment. Treating two 
liters of product decreases the cost for Pulmozyme treatment to $1,072 adding $412 to 
the cost of vector production when compared to the use of Benzonase. With the supply 
cost of a 20 liter clinical grade vector production estimated at approximately $25,000, 
the switch to Pulmozyme would increase the cost by approximately 1.6%. 
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D. Discussion 
 
 The studies presented here demonstrate that Pulmozyme can be utilized as 
an alternative to Benzonase for removing residual plasmid DNA from lentiviral vector 
products. Pulmozyme offers the advantage of being a human protein produced in 
Chinese Hamster Ovary (CHO) cells as opposed to the bacterially derived Benzonase. 
Most importantly, the availability of a pharmaceutical grade reagent will be important 
as vectors move from investigational agents into licensed products and the 
requirements for product purity escalate.   
 Incorporating the DNase treatment into the transfection process was 
evaluated as a means to decrease the time between product harvests and freeze down. 
While lentiviral vector half-life is longer than that of traditional gamma-retroviral 
vectors, efforts to insure a rapid freezing will help maximize the final vector titer 
(Higashikawa & Chang, 2001) and treatment at the end of transfection (Figure 5, 
protocol B) would minimize the time between vector harvest and freezing. The other 
advantage of DNase treatment in the transfection process is the subsequent media 
changes will greatly decrease the concentration of DNase in the final product. In 
contrast, treating the harvested vector leaves significant amounts of DNase in the final 
product (Zufferey, 2002) and exposing patients to foreign proteins has been associated 
with adverse events. For example, patients with pneumonia, treated with a bovine 
DNase, developed severe respiratory reactions due to contaminating proteins (Johnson, 
Goger, & Tillett, 1954; Lachmann, 1967; Raskin, 1968). Unfortunately, treatment at the 
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end of transfection was inferior to treating the harvested product in terms of DNA 
degradation. 
 The cause of the disparity observed between the two protocols is not readily 
apparent. Our findings suggest that although there does not appear to be any inhibition 
of the DNase by serum, there is still some degree of protection when complexed with 
calcium phosphate. This is apparent since Pulmozyme is able to degrade plasmid DNA 
complexed with calcium phosphate (Figure 9D), yet there are consistent levels of 
plasmid DNA detected by Q-PCR (Figures 7 and 8). This indicates that plasmid DNA 
complexed with calcium phosphate infers some resistance to DNase degradation, and is 
consistent with previously reported findings (Loyter et al., 1982). The ability to degrade 
the residual DNA more efficiently by treating the harvested vector is likely due to the 
dynamic and relatively unstable nature of the calcium phosphate complex over time 
(Jordan & Wurm, 2004). Whether the same degree of protection is observed with other 
transfection methods, such as liposome based, remains to be determined.  
 Although our findings indicate Pulmozyme® is a viable DNase, the timing and 
concentration will likely need to be tailored to the vector production method employed. 
Presently, there is considerable variability in large-scale lentiviral production methods, 
ranging from methods that provide minimal processing to those with extensive 
diafiltration, ion-exchange, and size separation (Merten et al., 2011; Slepushkin et al., 
2003; Transfiguracion, Jaalouk, Ghani, Galipeau, & Kamen, 2003). Purification steps are 
likely to reduce DNA, as well as decrease the amount of residual Pulmozyme in the final 
product. It is possible that lower concentrations of Pulmozyme could be utilized if 
 44 
 
subsequent purification steps contributed to plasmid DNA removal so that combined 
the level of DNA is decreased to undetectable levels. For clinical products, residual 
foreign proteins must also be minimized in order to avoid allergic reactions after vector 
administration. At present, the U.S. FDA has not set limits on the amount of residual 
DNase in a final product. The acceptable level may vary depending on whether the 
product is administered ex vivo or in vivo. Therefore, Pulmozyme removal should be 
considered in the design of downstream processing, with highly stringent processes 
used for vector injected directly into immune competent individuals.   
 The variability in production methods, along with evolving technology suggest 
that ongoing refinements make universal statements about DNase treatment difficult. 
Nevertheless, the ability to substitute Benzonase with an FDA approved reagent will 
improve the safety of vector products without compromising vector titer. This change 
will result in a minimal increase in the overall cost of clinical vector production. 
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III. Combining modifications to improve the utility of non-integrating lentiviral vectors 
 
A. Introduction 
 
 Lentiviral vectors have shown success in several clinical trials, including recent 
gene therapy trails for the treatment of Wiskott-Aldrich syndrome (Aiuti et al., 2013) 
and metachromatic leukodystrophy (Biffi et al., 2013). These early clinical trials with 
lentiviral vectors have utilized integrating vectors which rely on integrase mediated 
insertion. Integrase mediated insertion by lentiviral vectors is random in nature and 
poses an inherent risk of insertional mutagenesis (IM) whereby a vector inserts into a 
loci which results in the aberrant expression of nearby genes. The risk of IM was made 
apparent in an early clinical trial with gammaretroviral vectors, another class of 
retroviruses, which resulted in adverse events leading to oncogenesis in patients after 
treatment (Hacein-Bey-Abina et al., 2008). This led to an increased interest in lentiviral 
vectors which demonstrate an improved safety profile relative to gammaretroviral 
vectors (Modlich et al., 2009; Montini et al., 2006). However, while clinical use of 
lentiviral vectors has not resulted in any oncogenic events to date, there has been an 
incidence of clonal expansion and dominance of hematopoietic progenitors in a human 
gene therapy trial for β-thalassaemia due to lentiviral vector integration triggering 
aberrant splicing of the HMGA2 gene (Cavazzana-Calvo et al., 2010).  
 The inherent risk of IM associated with integrase mediated insertion has 
compelled the development of gene therapy methods which circumvent the necessity 
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for integrase mediated insertion. A promising avenue for safer gene therapy has been 
the advent of site-directed integration systems. Some of the more successful of these 
systems include engineered zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas systems (Joglekar et al., 2013; Lombardo et al., 2011; Lombardo et 
al., 2007; Mali, Esvelt, & Church, 2013; Osborn et al., 2013). However, these systems 
rely upon efficient delivery mechanisms such as lentiviral vectors to get into their target 
cells and/or provide templates for homologous recombination (HR) and require only 
transient expression of the components.  
 In order to provide a safer lentiviral vector where integrase mediated 
insertion is not required or warranted, non-integrating lentiviral vectors (NILV) have 
been developed. These vectors can provide transient expression in dividing cells and 
persistent episomal expression has been demonstrated for up to 9 months in non-
proliferating post-mitotic cells (Yanez-Munoz et al., 2006). NILV offer many of the 
advantages of lentiviral vectors such as a large packaging capacity, low immunogenicity 
and the ability to be pseudotyped, allowing for cell-type specific targeting not possible 
when using other methods such as plasmids. Lentiviral vectors can be induced to be 
non-integrating by incorporating several mutations. These include those that inhibit the 
catalytic activity of the integrase protein, mutating the integrase DNA attachment sites 
within the U3 and U5 regions of the LTRs, and by inducing the preferential production of 
1-LTR circular episomes and limiting the linear 2-LTR episomal form preferred for 
integrase mediated insertion by deletion of the 3’ polypurine tract (PPT) (Kantor et al., 
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2011). Modifications to the integrase DNA attachment sites have consisted of single or 
double base-pair mutations within the 12 base-pair U3 or 11 base-pair U5 regions. 
However, the effectiveness of these mutations proved to be inferior as compared to 
point mutations to the integrase protein. In an attempt to improve the functionality of 
integrase DNA attachment site mutations we have evaluated a novel mutation 
developed by a previous student in our lab, Guiandre Joseph (GJ), by ablating the entire 
U3 and U5 attachment sites. The rationale behind complete ablation, as opposed to 
point mutations, was to inhibit any latent binding to the attachment sites and to 
prevent the incidence of reversion mutations. Our previous analysis of vectors with the 
ablated U5 attachment site revealed loss of transgene expression. After further analysis 
we determined that the U5 attachment site was immediately adjacent to, and 
overlapping a reverse transcription primer binding site (PBS). Ablation of the U5 
attachment site likely resulted in inhibition of first strand synthesis during reverse 
transcription and loss of viable transcripts. In contrast, vectors containing the ablated 
U3 attachment site demonstrated significant and persistent transgene expression for up 
to three weeks post-transduction and this mutation was utilized for subsequent studies.  
 While integrase, attachment site, and PPT mutations can independently 
reduce the frequency of integration by several logs relative to integrating lentiviral 
vectors, they still demonstrate a low level of illegitimate integration. Combining 
mutations for inhibiting integration could help to reduce this frequency of illegitimate 
integration by NILV. Early studies combining integrase defective mutants with single or 
double base-pair mutations to the conserved terminal CA dinucleotides within the LTR 
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integrase DNA attachment sites (Apolonia et al., 2007; Nightingale et al., 2006) found no 
synergistic or additive effects. Recent studies evaluating the effectiveness of combining 
integrase and PPT mutant vectors have demonstrated more promising results. In two 
separate studies they were able to demonstrate that these elements acted 
independently and provided a threefold reduction in the frequency of illegitimate 
integration (Kantor et al., 2011; Tareen et al., 2014) as compared to the integrase 
mutation alone. However, given that gene therapy trials often treat in excess of 5 X 108 
cells per patient, a 3 fold reduction in integration may not provide a clinically significant 
improvement to safety when using these vectors.  
 As lentiviral vectors are entering the clinic and new technologies are being 
developed which incorporate them as delivery vehicles, it is imperative to provide the 
safest vector possible. To improve the utility of NILV for clinical applications it will be 
necessary to minimize illegitimate integration and improve transgene expression. As 
non-integrating lentiviral vectors have demonstrated a propensity for reversion 
mutations (Yanez-Munoz et al., 2006), a complete ablation of the integrase attachment 
sites as opposed to previously evaluated point mutations could permit a reduction in 
the frequency of illegitimate integration when combined with other modifications. NILV 
have also demonstrated reduced levels of transgene expression relative to integrating 
vectors. Recent studies have successfully evaluated suppression of trans- and cis- acting 
inhibitors to episomal transgene expression. In order to improve or maintain an 
adequate level of transgene expression when combining modifications to reduce 
illegitimate integration we have evaluated incorporating a large deletion of the U3 
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region within the LTRs. This modification has been shown to increase transgene 
expression by nearly threefold by removing cis-acting inhibitors to episomal expression 
(Bayer et al., 2008).  
 Here, we present an analysis of our novel U3 LTR integrase attachment site 
deletion mutation and the efficacy of combining it with an integrase D116N catalytic 
core mutation and a 3’ PPT deletion to reduce illegitimate integration and large U3 
deletion of cis-acting inhibitors to improve episomal transgene expression. We report 
that, independently, our novel attachment site mutation does not reduce illegitimate 
integration as significantly as an integrase catalytic core mutation, however, combining 
the LTR attachment site and integrase mutations provides a significant reduction in 
illegitimate integration as compared to either mutation independently. Furthermore, 
the addition of a 3’ PPT deleted mutation demonstrates an additional reduction in the 
frequency of illegitimate integration and the inclusion of a large U3 deletion results in 
significantly increased levels of transgene expression. Finally, we report that vectors 
with multiple modifications demonstrate transduction efficiency and stability similar to 
the unmodified parental vector. This provides support to their effectiveness as non-
integrating vectors and the additive effects among the modifications to reduce 
illegitimate integration.  
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B. Methods 
 
Cell culture and reagents 
 The production of lentiviral vector containing supernatant and the integration 
and expression analysis of lentiviral vector preparations was performed in HEK 293T and 
HEK 293 cells, respectively. Both HEK cell lines were obtained from American Type 
Culture Collection (Manassas, VA) and cultured in Dulbecco’s modified Eagle’s medium 
with Glutamax (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(FBS, HyClone, Logan, UT) and 100 units/ml penicillin-streptomycin (Pen-Strep, 
Invitrogen).  
 
Designing modified lentiviral vectors 
 Modifications to vector design were incorporated into the normal integrating 
lentiviral vector transfer plasmid pcDNA-CS-CGW, provided by Phillip Zoltick, and the 
packaging plasmid pMDL (Cell Genesys, San Francisco, CA) (Figure 10). The point 
mutation IN/D116N was introduced by former student GJ into pMDL by site directed 
mutagenesis for the production of integrase defective non-integrating lentiviral vectors 
(NILV). Deletion of the 12 base-pair integrase DNA attachment site within the U3 region 
of the transfer plasmid (LTRΔatt ) was performed by GJ via sub-cloning the 3’ LTR into a 
cloning vector by standard restriction site methods, followed by site directed 
mutagenesis to produce integration defective NILV. A deletion of the transfer plasmids 
3’ polypurine tract (ΔPPT) and a 274 base-pair portion of the LTR’s U3 region from base-
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pair 42-316 (ΔU3) were incorporated by standard restriction site insertion of the 
modified regions synthesized by GeneArt (Life Technologies, Grand Island, NY). All 
vector supernatants were produced by calcium phosphate transient transfection of HEK 
293T cells using a 3rd generation 4-plasmid system consisting of the transfer and 
packaging plasmids described above, along with a Rev expression plasmid (pRSV-rev) 
and the VSVG envelope expression plasmid (pMDG, Cell Genesys, San Francisco, CA). 
 
Physical titers 
 The physical titer of lentiviral vector supernatant was determined for 
normalization of vector concentration prior to transduction. Physical titer was obtained 
using a commercially available p24gag ELISA kit (Beckman Coulter) to measure p24 
antigen using serial dilutions of vector supernatant post-transfection.  The DNA titer was 
measured post-transduction of HEK 293 cells in order to determine vector copy number 
by reverse transcription Q-PCR analysis. Q-PCR was performed for detection of psi-gag 
sequences as previously described (Sastry et al., 2003).  
 
Integration analysis 
 The frequency of integration was determined using an antibiotic resistant 
colony formation titer assay. The optimal dosage of the antibiotic Zeocin™ (Life 
Technologies, Carlsbad, CA) for use in our assay was determined to be 500 µg/ml using 
HEK 293 cells. To determine the vector infectious titer, HEK 293 cells were transduced 
with 8 μg/ml of polybrene (Sigma-Aldrich, St. Louis, MO) and serial dilutions of viral 
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supernatant containing a Bleomycin resistance transgene normalized by p24 content as 
described above. Selection media was added 48 hours post-transduction and changed 
approximately every 48 hours. The transduced cells were incubated for up to three 
weeks post-transduction to allow for loss and/or dilution of episomal vector to cell 
division, selecting for colonies with integrated vector. Viable colonies with integrated 
vector were then counted to calculate infectious titer based on the corresponding 
dilution by washing in PBS and staining with methylene blue in methanol. 
 
Expression analysis 
 The level of transgene expression in transduced cells was measured by flow 
cytometry for GFP expression as previously described(Sastry et al., 2002) using a 
FACSCalibur APC or LSRII cytometer (Becton-Dickinson, San Jose, CA) and FlowJo 
analysis software (Tree Star, Inc., Ashland, OR). The level of transgene expression was 
determined by comparing the percent of GFP positive cells and median fluorescence 
intensity (MFI) of mutant vectors to a normal integrating control vector. 
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Figure 10. Schematic demonstrating several modifications incorporated into NILV 
design. Mutations and deletions incorporated in novel NILV intended to reduce 
illegitimate integration and improve transgene expression. Modifications are illustrated 
in red. The transfer vector presents three modifications: a deletion of the 3’ polypurine 
tract (ΔPPT) at the terminal end of the vector backbone, immediately adjacent to the 3’ 
LTR; a deletion of the U3 integrase attachment site (att) in the 3’ LTR which is copied to 
the 5’ LTR following reverse transcription as indicated by the red arrow (LTRΔatt); and a 
large deletion of 274 base-pairs in the U3 region (ΔU3) in addition to the previous self-
inactivation deletion (SIN) included in 3rd generation LV. The packaging plasmid 
demonstrates a mutation to the pol gene region (IN/D116N) in the catalytic core domain 
of integrase. 
 
 
 
 
 
 54 
 
C. Results 
 
Novel U3 LTR attachment site deleted NILV have a reduced frequency of integration  
 The utility of a NILV is almost entirely dependent upon its efficiency of 
inhibiting or minimizing the frequency of integration. It is therefore pertinent that when 
developing NILV for clinical use, that any illegitimate integration is thoroughly 
evaluated. This is necessary in order to provide for informed risk assessments when 
using these vectors for transient or sustained episomal expression and where insertional 
mutagenesis is a concern.  
 The frequency of integration by a novel U3 LTR integrase attachment site 
deleted NILV (LTRΔatt) expressing a bleomycin resistance transgene was assessed in 
three separate experiments by an antibiotic colony formation assay following drug 
selection of transduced HEK 293 cells. In Figure 11 the efficiency of the novel NILV, 
LTRΔatt, to reduce integration frequency was compared relative to an integration 
competent vector (ICV), an NILV with a point mutation in the catalytic core domain of 
integrase (IN/D116N) and an NILV containing both modifications to the attachment site 
and integrase (LTRΔatt-IN/D116N).  
 The three NILV all reduced the frequency of integration approximately two 
logs below that of an ICV. Similar to LTR integrase attachment site mutant vectors with 
single or double base-pair mutations reported in the literature, our novel vector 
(LTRΔatt) integrated at a significantly higher frequency than the more commonly used 
integrase catalytic core mutant (IN/D116N). Interestingly, in contrast to other reports 
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when combining integrase and attachment site mutations (Apolonia et al., 2007; 
Nightingale et al., 2006), the double mutant (LTRΔatt-IN/D116N) significantly reduced 
the frequency of integration by up to 4 fold as compared to either mutation 
independently. The complete ablation of the U3 LTR integrase attachment site 
demonstrates a synergistic reduction in the frequency of illegitimate integration when 
combined with the integrase catalytic core mutation. These findings laid the 
groundwork for investigating the combining of multiple modifications to improve the 
efficacy of NILV. 
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Figure 11. A deletion of the U3 integrase attachment site can effectively reduce the 
frequency of integration in an NILV. Average antibiotic resistant colony formation titer 
assay results from two independent experiments comparing the frequency of 
integration among an integration competent vector (ICV), a U3 LTR integrase 
attachment site mutant NILV (LTRΔatt), an integrase deficient NILV (IN/D116N), and a 
double mutant NILV (LTRΔatt-IN/D116N). Y-axis represents infectious units/ml of vector 
supernatant. Error bars indicate standard deviation of the mean. Asterisk indicate a 
significant difference between vectors. * - p < 0.05; ** - p < 0.005 
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Multiple modifications to vector design can be combined to improve the utility of NILV 
 It has been reported that point mutations to the LTR integrase attachment 
sites have not provided as significant of a reduction in the frequency of integration as 
compared to integrase catalytic core mutations, similar to the results with LTRΔatt. It 
has also been reported that combining LTR attachment site mutations with integrase 
mutations provided no further reduction in the frequency of integration as compared to 
using the integrase mutants alone (Apolonia et al., 2007; Nightingale et al., 2006). The 
finding of reduced integrations when LTRΔatt was combined with the D116N integrase 
mutation encouraged us to evaluate other modifications that could further improve 
NILV.  
 Two additional modifications to the transfer vector plasmid reported in the 
literature were investigated in hopes of further improving NILV function. These include a 
deletion of the 3’ PPT to decrease integration by promoting the formation of 1-LTR 
circles and reducing linear episomes (Kantor et al., 2011). While the above modifications 
were aimed at decreasing integration, we also evaluated a 273 base-pair deletion in the 
U3 region of the LTR that removes cis-acting inhibitors and has the potential to increase 
transgene expression. The mechanism by which these sequences inhibit transgene 
expression is unclear, however, early studies have indicated their existence (Bayer et al., 
2008; Hoover et al., 1996; Y. Lu, Stenzel, Sodroski, & Haseltine, 1989; Rosen, Sodroski, & 
Haseltine, 1985). The ΔU3 and ΔPPT modifications were incorporated into either an 
integration competent vector (CS-CZW) or the attachment site mutant (LTRΔatt) 
transfer vector plasmid and combined with either an integrase-competent (pMDL) or 
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integrase defective (IN/D116N) packaging plasmid. The resulting plasmids were verified 
by sequencing analysis and p24 ELISA analysis of vector supernatant to ensure the 
modifications did not adversely affect vector titer (data not shown). Each vector 
modification was evaluated independently and in combination with each variation for a 
total of 16 vectors containing either a bleomycin resistance or GFP transgene for 
assessing integration or expression, respectively (Table 1). 
 
Combining multiple modifications for inhibiting vector integration can reduce the 
frequency of illegitimate integration by NILV 
 In order to determine the efficacy of modified NILV, we first sought to 
evaluate the frequency of integration utilizing vectors containing a bleomycin resistance 
transgene in a quantitative colony formation assay. We first evaluated the individual 
mutations, that each inhibit a different point in the vector life cycle, in order to 
determine their efficacy independently and to provide a baseline on their integration 
frequency (Figure 12). The ΔU3 modification had no effect on integration and performed 
similar to the ICV (CS-CZW). The NILV modifications (ΔPPT, IN/D116N and LTRΔatt) 
exhibited up to a three log reduction in integration frequency. Individually, vectors with 
a single modification integrated at an expected frequency relative to results in the 
literature (Kantor et al., 2011; Negri et al., 2007) 
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Table 1. Combining four modifications to lentiviral vector design results in 16 viable 
vectors for integration and expression analysis. Representation of the 16 different 
lentiviral vector combinations possible when combining transfer vector modifications 
with a packaging plasmid mutation. Shaded areas indicate the modifications included 
per each vector combination in each row. CS-CZW – Normal integration competent 
transfer vector backbone containing either a bleomycin as shown or GFP transgene (CS-
CGW); LTRΔatt – LTR U3 integrase attachment site deletion; ΔPPT – 3’ polypurine tract 
deletion; ΔU3 – 273 base-pair U3 deletion; pMDL – packaging plasmid with an intact 
integrase; IN/D116N – a integrase catalytic core point mutation at residue D116. 
 
 
 
CS-CZW LTRΔatt ΔPPT ΔU3 pMDL IN/D116N
Packaging PlasmidTransfer Vector Plasmid
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 Figure 12. The frequency of integration can be reduced independently in NILV by 
incorporation of mutations that inhibit integration at different points in the viral life 
cycle. Average bleomycin resistant colony formation results from two experiments 
comparing the frequency of integration among individual mutations to lentiviral vector 
design. From left to right the vectors analyzed are: an integration competent vector (CS-
CZW), an integrating vector with a large deletion of cis-acting inhibitors to episomal 
transgene expression in the U3 region of the vectors LTRs (ΔU3), an NILV with a deletion 
of the vectors 3’ polypurine tract (ΔPPT), an integrase deficient NILV (IN/D116N), and a 
U3 LTR integrase attachment site mutant NILV (LTRΔatt). Y-axis represents infectious 
units/ml of vector supernatant. Error bars indicate standard deviation of the mean. 
Asterisk indicate a significant difference relative to the integration competent vector 
(CS-CZW). * - p < 0.05; n.s. – not significant. 
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 When pairing the modifications with each other the expected results were 
also observed. Combining each NILV vector with the ΔU3 modification (Figure 13A) 
resulted in an increase in the frequency of integration, indicating that removing cis-
acting inhibitors to episomal transgene expression can result in more viable episomes 
which can then provide substrates for illegitimate integration. 
 Pairing each NILV mutation with the ΔPPT modification provided modest 
reductions in integration frequency (Figure 13B). Similar to results reported by Kantor et 
al. and Tareen et al., pairing ΔPPT with IN/D116N provided a further reduction in 
integration as compared to either mutation individually, indicating that each 
modification works independently to inhibit integration (Kantor et al., 2011; Tareen et 
al., 2014). Interestingly, combining the ΔPPT modification with LTRΔatt resulted in a 
frequency of integration similar to that of the ΔPPT alone, with no further reduction in 
integration frequency. This may be due to the fact that the two modifications are 
immediately juxtaposed to one another in the vector possibly providing redundant 
mechanisms of inhibiting integration. In previous work by GJ, analysis of episomal forms 
indicated a persistent predominance of 1-LTR circles relative to linear and 2-LTR forms 
by LTRΔatt, similar to effect observed when deleting the 3’ PPT to induce the 
preferential formation of 1-LTR circles. In contrast, combining the IN/D116N mutation 
with LTRΔatt provided the greatest reduction in integration frequency (Figure 13C, D). 
This is likely due to an additive effect between two independent non-redundant 
mechanisms for inhibiting integration.  
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Figure 13. The frequency of integration can be reduced in NILV by pairing 
modifications to vector design for inhibiting vector integration. Average bleomycin 
resistant colony formation assay results from two experiments comparing the frequency 
of integration among paired mutations to LV design. The horizontal axis designates the 
vector or independent modification (dark gray bars) and pairing it with the indicated 
mutation (light gray bars). CS-CZW - an integration competent vector; (A) ΔU3 
modification - a vector with a U3 deletion of cis-acting inhibitors to transgene 
expression; (B) ΔPPT modification- an NILV with a deletion of the vectors 3’ polypurine 
tract; (C) IN/D116N modification - an integrase deficient NILV; (D) LTRΔatt modification - 
a U3 LTR integrase attachment site mutant NILV. Error bars indicate SD of the mean. 
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 Next, we evaluated the efficacy of combining three or more of the 
modifications to vector design in order to elucidate their combined effect on integration 
frequency. Combining three or more of the modifications to vector design provided the 
most consistent reduction in illegitimate integration frequency (Figure 14). Vector 
combinations with at least two non-redundant modifications for reducing integration 
frequency were able to efficiently inhibit illegitimate integration. The presence of the 
ΔU3 modification resulted in a significant increase in illegitimate integration when 
combined with LTRΔatt-IN/D116N and LTRΔatt-ΔPPT as compared to the other 
combinations in this group. This was especially evident in the vector combining the ΔU3 
deletion with the possibly redundant mutations LTRΔatt and ΔPPT. However, a vector 
with all 3 integration inhibiting modifications, LTRΔatt-ΔPPT-IN/D116N, did not 
demonstrate any significant increase in illegitimate integrate when combined with the 
ΔU3 deletion. This demonstrates the ability of combined integrase inhibiting 
modifications to reduce illegitimate integration in the presence of more viable 
episomes. 
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Figure 14. The frequency of integration can be reduced in NILV by combining multiple 
modifications to vector design. Average bleomycin resistant colony formation assay 
results from two experiments comparing the frequency of integration among combining 
multiple modifications to lentiviral vector design. CS-CZW - an integration competent 
vector; ΔU3 - a U3 deletion of cis-acting inhibitors to episomal transgene expression in 
the LTRs; ΔPPT - a deletion of the vectors 3’ polypurine tract; IN/D116N - an integrase 
deficient NILV modification; LTRΔatt - a U3 LTR integrase attachment site mutant NILV 
modification. Error bars indicate standard deviation of the mean. Y-axis indicates 
infectious units/ml of vector supernatant. Asterisk indicate a significant difference 
relative to the other NILV combinations. * - p < 0.05; ** – p < 0.005. 
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Removing cis-acting inhibitors to episomal transgene expression can improve the level 
of transgene expression when combined with multiple modifications that inhibit 
vector integration 
 An important factor plaguing the development of NILV has been significantly 
reduced levels of transgene expression relative to integration competent vectors (ICV). 
In order to analyze our modifications to vector design we utilized a GFP transgene and 
assessed vector expression by flow cytometry (Figure 15).  
 The three modifications for reducing integration frequency (ΔPPT, IN/D116N 
and LTRΔatt) individually produced levels of transgene expression between one and two 
logs below that of a wild-type vector as previously demonstrated for NILV (Bayer et al., 
2008; Kantor et al., 2011; Naldini et al., 1996; Philippe et al., 2006; Vargas et al., 2004).  
  The addition of the ΔU3 modification was able to significantly improve the 
level of expression of a wild-type vector at 1.3X fold increased MFI. When paired with 
the ΔU3 deletion there was no significant improvement in expression levels with the 
ΔPPT or LTRΔatt modifications. However, when combining the ΔU3 with the IN/D116N 
modification, there was a 1.6X increase in expression likely due to more viable episomal 
forms in the absence of cis-acting inhibitors removed by the ΔU3 deletion.  
 There was no significant effect on expression when pairing the ΔPPT deletion 
with the integrase mutation IN/D116N, in line with results by Kantor et al. using an 
integrase mutant D64E NILV (Kantor et al., 2011). Pairing the IN/D116N mutation with 
LTRΔatt modification resulted in a significant decrease in expression. This combination 
demonstrated one of the lowest frequencies of integration, thus having fewer 
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integrated vector and less viable episomal forms in the absence of ΔU3 available to 
express the transgene. 
 Combining three or more modifications to vector design had variable results. 
The ΔU3 modification was unable to provide any significant improvement in expression 
to the IN/D116N-ΔPPT or LTRΔatt-IN/D116N pairs. However, combining the ΔU3 
deletion with the LTRΔatt-ΔPPT pair was able to significantly improve the expression of 
this combination by 2.8X giving the best expression for any of the vector combinations. 
This is probably due to having more viable episomal forms and a higher frequency of 
illegitimate integration providing better transgene expression. Combining ΔPPT, 
LTRΔatt, and IN/D116N provided a reduced level of transgene expression, likely due to 
the combination of all three modifications for reducing integration frequency without 
the ΔU3 deletion to remove cis-acting inhibitors. Adding the ΔU3 deletion to this 
combination, creating a vector with all four modifications, was able to significantly 
rescue the level of transgene expression. This vector with all four modifications to 
vector design gave the second best level of transgene expression, but with a significantly 
lower frequency of integration relative to the LTRΔatt-ΔPPT-ΔU3 vector which also 
demonstrated significantly improved transgene expression (Figure 14). 
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Figure 15. Combining a ΔU3 modification with multiple modifications to reduce 
integration frequency can maintain and/or improve transgene expression levels. 
Average flow cytometry for GFP expression results from two experiments comparing the 
levels of transgene expression among combining modifications to lentiviral vector 
design with a ΔU3 deletion for removing inhibitors to transgene expression. Black bars 
indicate the geometric mean fluorescence intensity (MFI) for the indicated vector on the 
x-axis, gray bars indicate the MFI when combining the indicated vector with the ΔU3 
deletion. Wild-type - normal integrating vector (CS-CGW); ΔPPT - a deletion of the 
vectors 3’ polypurine tract; IN/D116N - an integrase deficient NILV modification; LTRΔatt 
- a U3 LTR integrase attachment site mutant NILV modification. Error bars indicate 
standard deviation of the mean. Asterisk indicate a significant difference relative to 
combination with the ΔU3 deletion. * - p < 0.05; ** – p < 0.005. 
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NILV with multiple modifications demonstrate expected copy number trends and 
demonstrate levels of transgene expression relative to their frequency of integration 
 In order to further verify the non-integrating nature of the NILV, copy number 
was evaluated by RT-Q-PCR up to 96 hours post-transduction. Since HEK 293 cells 
double approximately every 24 hours, an optimal NILV population would be expected to 
demonstrate a reduction in copy number of roughly 50% with each cell division. For this 
analysis three NILV with differing frequencies of integration were selected (LTRΔatt-
ΔU3, LTRΔatt-ΔU3-ΔPPT and LTRΔatt-ΔU3-ΔPPT-IN/D116N). The vector combinations 
were compared over time relative to an integration competent vector (CS-CGW). 
Regardless of their frequency of integration, each NILV demonstrated the predicted 
reduction in copy number over time (Figure 16B).  
 The low level of illegitimate integration observed with these NILV would likely 
be unable to affect any observable increase in copy number until a much later time 
allowing for sufficient replication. However, the levels of transgene expression obtained 
by the NILV demonstrated an increase relative to integration frequency (Figure 16A). 
The LTRΔatt- ΔU3 NILV showed a consistent increase in expression over time, 
demonstrating a correlation with the higher level of illegitimate integration by this 
vector relative to the other NILV. This is in line with work by Pelascini et al. where 
episomal NILV were considered preferential targets for epigenetic silencing by 
chromatin-remodeling histone deacetylation (Pelascini et al., 2013), thus increased 
integration would provide for increased levels of transgene expression with similar copy 
number.  
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Figure 16. NILV demonstrate expected trends for copy number over time while 
providing levels of transgene expression relative to their frequency of integration.  
(A) Flow cytometry results for MFI of GFP expression at 48 (black bars), 72 (gray bars) 
and 96 hours (white bars) post-transduction. Error bars indicate standard deviation of 
the mean among three replicates per time point. (B) Vector copy number determined 
from RT-Q-PCR analysis measured at 48 (black bars), 72 (gray bars) and 96 hour (white 
bars) time points post-transduction. Horizontal axes indicate the vector mutations per 
vector. CS-CGW - an integration competent vector; ΔU3 - a U3 deletion of cis-acting 
inhibitors to episomal transgene expression in the LTRs; ΔPPT - a deletion of the vectors 
3’ polypurine tract; IN/D116N - an integrase deficient NILV modification; LTRΔatt - a U3 
LTR integrase attachment site mutant NILV modification. 
 
 
 
 70 
 
NILV demonstrate levels of transgene expression near the approximation of their 
theoretical maximum and relative to their frequency of integration 
 An inherent difficulty in analyzing NILV transduction efficiency and stability in 
dividing cells is the dilution of transduced cells with each cell division. This can lend to 
an under-estimation of NILV activity. Integrating lentiviral vectors can maintain a 
constant percentage of transduced cells over time by concomitant replication with each 
cell division. The transduction efficiency of NILV, on the other hand, is limited to the 
number of cells available for infection at the time of transduction due to their episomal 
nature and lack of origins of replication.  
 In order to determine the transduction efficiency and stability of NILV in 
dividing cells, one must take into account the number of cells present at transduction 
and their rate of replication. The initial percentage of cells containing NILV is expected 
to decrease by 50% with each cell division assuming no integration and one episomal 
copy per cell. Any significant deviation from this trend by NILV would be indicative of 
illegitimate integration resulting in higher titers, or loss of episomes by degradation or 
silencing resulting in decreasing titer.  
 In order to account for these characteristics of NILV, the total number of cells 
were counted at the day of transduction (Day 1) and 96, 120, and 144 hours post-
transduction. The percentage of GFP positive cells were measured by flow cytometry at 
96, 120, and 144 hours’ post-transduction allowing adequate time for transgene 
expression. For this analysis three NILV with differing frequencies of illegitimate 
integration were compared relative to an ICV (CS-CGW), including LTRΔatt-ΔU3, 
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LTRΔatt-ΔU3-ΔPPT and LTRΔatt-ΔU3-ΔPPT-IN/D116N. For the analysis two reference 
lines were plotted. A line indicating the total number of cells at each time point (Figure 
17, light gray, small, dotted line), which would be indicative of 100% integrated 
transduction efficiency. Also, a line indicating the number of cells present at 
transduction (Figure 17, dark gray, large, dotted line), indicative of the maximum 
transduction efficiency possible for an NILV without any significant frequency of 
illegitimate integration. The ICV demonstrated the expected expression pattern (Figure 
17, light gray, dashed line), maintaining an approximately constant percentage of 
transduced cells over time relative to their initial efficiency of infection and the number 
of cells at each time point. The vector LTRΔatt-ΔU3, the NILV analyzed with the highest 
frequency of illegitimate integration, demonstrated a similar trend albeit with a 
significantly reduced percentage of transduced cells (Figure 17, black, dashed line). 
LTRΔatt-ΔU3-ΔPPT gave an initial transduction efficiency at 72 hours post-transduction 
of 67% relative to the number of cells available at the time of transduction (Figure 17, 
solid, black line). The percentage of transduced cells remained below the theoretical 
maximum at 96 hours while slowly increasing until after 120 hours where they exceeded 
this maximum. This is possible due to its lower frequency of illegitimate integration 
requiring additional time to replicate and begin to increase the titer to an observable 
level. However, the percentage of transduced cells relative to the total number of cells 
at this time point is very low at 6%, leaving room for experimental error due to the 
limitations of the FACS machine and possible false positives. The vector with the lowest 
frequency of integration analyzed, LTRΔatt-ΔU3-ΔPPT-IN/D116N, showed a similar trend 
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while remaining at more consistent level below the theoretical maximum and did not 
exceed it until a later time point (Figure 17, solid, gray line). This demonstrates the 
significantly lower frequency of integration by this vector, indicating stable episomal 
expression over time with minimal effects observable due to illegitimate integration. 
These four vectors demonstrate the improved efficiency of combining multiple 
modifications to reduce illegitimate integration providing a safer and more effective tool 
for gene therapy applications.  
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Figure 17. NILV demonstrate transduction efficiencies representative of their 
frequency of illegitimate integration. Cell counts (dotted lines) and flow cytometry 
results for infectious titer based on the percentage of GFP positive cells. Large, dark gray 
dotted line denotes the average number cells at the day of transduction as a reference 
for NILV transduction efficiency. Small, light gray dotted line represents the average 
number of cells at each time point analyzed as a reference for integration competent 
vector transduction efficiency and illegitimate integration by NILV. Solid and dashed 
lines indicate average titer results. Gray dashed line –integration competent vector (CS-
CGW); Black dashed line – an NILV with a high frequency of illegitimate integration 
(LTRΔatt-ΔU3); Solid black line – NILV (LTRΔatt-ΔU3-ΔPPT) with the highest MFI; Solid 
gray line – NILV (LTRΔatt-ΔU3-ΔPPT-IN/D116N) with the optimal ratio of transgene 
expression and reduced illegitimate integration. Error bars indicate standard deviation 
of the mean for three replicates at each time point. 
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D. Discussion 
 
 The goal of this work was to evaluate a novel NILV and assess the value of 
combining it with multiple modifications to vector design in order to improve their 
safety and utility for gene therapy applications. The evaluation of a novel NILV (LTRΔatt), 
with a deletion of the 12 base-pair integrase DNA attachment site within the U3 region 
of the 3’ LTR, demonstrated a significant reduction in the frequency of integration 
relative to an ICV. However, while LTRΔatt provided a significant reduction in the 
frequency of integration it proved inferior to reduction in illegitimate integration 
achieved by an integrase mutant NILV, similar to what others have observed when 
evaluating point mutations within the integrase DNA attachment sites (Apolonia et al., 
2007; Masuda et al., 1995; Nightingale et al., 2006). Of greater interest, this initial work 
demonstrated an improvement in the reduction of integration frequency when 
combining this novel NILV modification with a mutation in the catalytic core domain of 
integrase (IN/D116N). This finding suggested that combining multiple modifications to 
inhibit integration can improve the safety profile of NILV by significantly reducing the 
frequency of illegitimate integrations. 
 To further investigate these findings, a deletion of the vector’s 3’ polypurine 
tract (ΔPPT), intended to further reduce the frequency of integration, was explored 
along with a large deletion within the U3 region of the vector’s LTRs (ΔU3) aimed at 
improving the level of transgene expression in NILV. These additional modifications 
were combined with the LTRΔatt and the IN/D116N modifications to produce two sets 
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of 16 different vectors with either a GFP or Bleomycin resistance transgene. Our 
integration analysis results demonstrated a synergistic effect upon combining 
modifications to reduce integration providing the groundwork for combining other 
modifications which may further improve the profile of NILV. As NILV have historically 
demonstrated a reduced level of transgene expression relative to ICV, the combination 
of multiple modifications to reduce integration posed the risk of a further reduction to 
expression levels. In order to compensate for the possibility of this phenomenon, we 
evaluated the addition of a ΔU3 deletion of cis-acting inhibitors to transgene expression. 
We demonstrated that incorporation of the ΔU3 deletion was able to rescue the level of 
transgene expression in NILV with combinations of multiple modifications to reduce 
illegitimate integration. These results demonstrate that combining NILV modifications 
can improve their transgene expression and safety profile.  
 We then sought to further confirm the integration deficient nature of the 
NILV combinations with a more in depth analysis. We chose three NILV for analysis that 
displayed optimal levels of transgene expression and varying frequencies of illegitimate 
integration in order to elucidate how these factors affect their behavior. We found that, 
regardless of integration frequency, the NILV all demonstrated reductions in copy 
number over time as expected in actively dividing cells. However, as NILV transgene 
expression levels are expected to remain constant or possibly decline over time, vectors 
with increased frequencies of illegitimate integration would demonstrated relative 
trends of increased transgene expression due to integrated vector replicating with each 
cell division.  
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 Finally, we took an in depth look at the transduction efficiency of NILV by 
comparing the percentage of transduced cells with the number of cells present over 
time. We were able to demonstrate that NILV are able to achieve comparable levels of 
transduction efficiency relative to ICV. Our results indicate that our novel NILV 
combinations are able to efficiently transduce cells and provide levels of transgene 
expression and rates of integration superior to current NILV. 
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IV. Modified insertion site analysis facilitates the elucidation of a unique mode of 
insertion presented by a novel U3 LTR integrase attachment site deleted non-
integrating lentiviral vector mutation 
 
A. Introduction 
 The use of viral vectors for clinical applications has been steadily increasing as 
they have been continually optimized and demonstrate a safer profile relative to early 
viral vectors. As new systems are developed that may provide potentially increased 
safety, the components of these systems will require intense scrutiny in order to assess 
their applicability in patients. Site-directed integration systems, including engineered 
zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
clustered regularly interspaced short palindromic repeats (CRISPR)-Cas systems 
(Joglekar et al., 2013; Lombardo et al., 2011; Lombardo et al., 2007; Mali et al., 2013; 
Osborn et al., 2013), have recently demonstrated promising clinical utility. These 
systems can improve the safety of gene therapy by omitting the necessity for viral-
mediated integration and the risk of insertional mutagenesis and facilitate insertion into 
or correction of specific loci. However, systems such as these still require efficient 
mechanisms for introduction into a target cell and trafficking to the nucleus. Lentiviral 
vectors are an effective gene therapy tool for this application with their large packaging 
capacity, broad tropism through pseudotyping, and their ability to transduce non-
dividing cells, among other beneficial characteristics. However, wild-type lentiviral 
vectors with integrase-mediated insertion can detract from the advantages of using site-
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directed integration. While lentiviral vectors have not demonstrated any severe adverse 
effects as observed with early gamma retroviral vectors due to insertional mutagenesis 
(Braun et al., 2014; Hacein-Bey-Abina et al., 2008; Howe et al., 2008; Ott et al., 2006), 
the risk will persist with the random nature of integrase-mediated insertion. This was 
made evident in a recent gene therapy trial for β-thalassaemia where integrase-
mediated lentiviral vector insertion resulted in a dominant cell clone due to 
transcriptional activation of HMGA2 (Cavazzana-Calvo et al., 2010).  
 Non-integrating lentiviral vectors (NILV) provide a viable alternative to 
integration-competent viral vector systems, with a reduced risk of insertional 
mutagenesis while retaining many of the benefits of lentiviral vectors. NILV can provide 
for transient expression of site-directed integration systems and/or their templates for 
homologous recombination, reducing the risks associated with persistent expression 
and the odds of off-target insertions. Other clinical applications for NILV include 
vaccination and cytotoxic cancer therapies, among others. However, while NILV can 
provide a safer alternative to integration competent vectors, they still retain a low level 
of illegitimate integration which must be accounted for. We and others have evaluated 
combining modifications to reduce the frequency of illegitimate integration in NILV, 
however it is unlikely that a complete ablation of illegitimate integration is feasible. The 
majority of illegitimate integrations by NILV appear to occur due to non-integrase-
mediated methods of insertion (Gaur & Leavitt, 1998; Matrai et al., 2011; Nightingale et 
al., 2006), similar to integrations observed with other non-integrating systems at sites of 
chromosomal breakage through homologous recombination or non-homologous end-
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joining pathways (Koyama et al., 2013; D. G. Miller et al., 2004). In order for NILV to 
meet stringent requirements for progression into the clinic, it will be necessary to 
thoroughly scrutinize any illegitimate integrations. This will require methods to 
accurately analyze these insertion sites during development and for follow up of 
patients post gene therapy treatment as set for in FDA guidelines (Guidance for 
Industry: Gene Therapy Clinical Trials – Observing Subjects for Delayed Adverse Events).  
 Techniques previously available for the analysis of vector insertion sites 
include ligation-mediated PCR (LM-PCR) (Smith, 1992), linear amplification-mediated 
PCR (LAM-PCR) (Schmidt et al., 2007), and non-restrictive LAM-PCR (nrLAM-PCR) 
(Gabriel et al., 2009). While these methods can accurately identify the majority of vector 
insertion sites when analyzing integration competent vectors, these methods lack the 
sensitivity to account for the variability observed in NILV insertion sites. These methods 
rely upon intact vector LTRs for the capture and amplification of vector insertion sites. 
The majority of NILV, which integrate via non-integrase mediated insertion, have 
presented large deletions and/or insertions at the vector-genome junction including 
large truncations or ablations of the vectors LTR (Koyama et al., 2013; Matrai et al., 
2011; Nightingale et al., 2006) which could result in the loss of capture by these 
methods. Techniques for accurately analyzing NILV insertion sites have previously 
employed the use of cloning vectors in order to assess the features of the vector-
genome junction. These techniques can be very labor and time intensive and are not 
feasible for any high-throughput analysis. Recently developed techniques for analysis of 
vector insertion sites have utilized sonication to shear the genome of transduced cells, 
 80 
 
followed by capture and amplification of fragments containing vector-genome junctions 
(De Ravin et al., 2014; S. Zhou et al., 2014). However, these techniques also rely upon 
intact LTR sequences in order to capture the fragments containing vector insertion sites. 
In order to evaluate NILV insertion sites with sufficient sensitivity and in a high-
throughput manner, existing techniques will need to be modified or new techniques 
developed in order to facilitate their analysis. 
In this study, we sought to evaluate the insertion sites of clonal populations 
transduced by either a wild-type lentiviral vector, a novel LTR integrase attachment site 
mutant NILV (LTRΔatt), an integrase deficient NILV (IN/D116N), or a double mutant 
containing both mutations (LTRΔatt-IN/D116N). We have previously demonstrated that 
our novel LTRΔatt vector provides a significantly higher frequency of illegitimate 
integration as compared to IN/D116N and that combining the mutations appears to 
result in a further reduction in integration frequency as compared to either mutation 
independently. We sought to analyze the vector-genome junctions of these vectors in 
order to elucidate the mechanisms behind their illegitimate integration which may lend 
to explaining the disparity observed in the frequency of integration with our novel 
LTRΔatt vector. To capture and analyze the vector insertion sites we employed LAM-PCR 
utilizing either 454 pyrosequencing or Illumina MiSeq platform. We also adapted 
protocols for insertion site capture utilizing sonication-mediated genomic fragmentation 
and Illumina MiSeq sequencing in an attempt to improve the capture and analysis of 
NILV insertion sites. We demonstrate that a reliance upon intact LTR fragments in 
methodologies for vector insertion site capture and amplification can hamper the ability 
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to evaluate NILV insertion sites with their variable vector-genome junction features. 
Accounting for the possibility of LTR truncations in protocols for NILV insertion site 
capture provides for improved analysis.  
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B. Methods 
 
Isolating Clonal DNA 
 Individual clones were selected by transducing HEK 293 cells with serial 
dilutions of vector supernatant containing a Bleomycin resistance transgene. The 
vectors for transduction included an integration competent vector (CS-CZW), an 
integrase catalytic core mutant NILV (IN/D116N), a novel LTR U3 integrase attachment 
site deleted mutant NILV (LTRΔatt), and a double mutant containing both the integrase 
and attachment site mutations (LTRΔatt –IN/D116N). Transduced cells were expanded 
in Zeocin™ (Life Technologies, Carlsbad, CA) containing selection media for up to three 
weeks post-transduction. Individual colonies were then isolated with cloning disks and 
expanded. Genomic DNA from the expanded clones was extracted using the Puregene 
DNA Purification Kit (Gentra Systems, Inc., Minneapolis, MN). 
 
Insertion Site Capture 
 For the first two experiments the vector-genome junctions were amplified by 
linear amplification mediated PCR (LAM-PCR) off of the 3’ LTR as previously described 
(Schmidt et al., 2007). Briefly (Figure 18), 200 ng of genomic DNA was amplified with 
two rounds of 50 cycle linear PCR using a biotinylated LTR-specific primer. The single 
stranded PCR products were captured with streptavidin coated magnetic beads and 
double stranded using a Klenow enzyme and hexanucleotide primers. The bound, 
double stranded products were digested with the restriction enzyme Tsp509I (New 
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England Biolabs) and a linker cassette was ligated onto the digested sticky end. Nested 
exponential PCR was then performed using LTR-specific and linker cassette-specific 
primers for the first round of PCR. During the second PCR iteration of the nested PCR, 
primers containing sequencing adapters and multiplex identifiers/indexes were 
incorporated for Roche 454 or MiSeq library preparation.  
 For our third experiment the vector-genome junctions were amplified by 
modified techniques adapted from Ravin, et al and Zhou, et al (De Ravin et al., 2014; S. 
Zhou et al., 2014). Briefly, to perform the modified technique for surveying vector 
insertion sites the genomic DNA was first sheared to an approximate size of 1,000 bp 
using Covaris sonication (Covaris, Wohurn, MA). Fragment size was evaluated using the 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA). Starting with 1000 ng 
of sheared fragments, the ends were repaired using the NEBNext End Repair Module 
(NEB, Ipswich, MA) and 3’ dA-tailed with the NEBNext dA-Tailing Module (NEB, Ipswich, 
MA). Products greater than ~300 bp were selected and purified using a 0.8:1 ratio of 
AMPure XP beads (Beckman Coulter, Brea, CA) to dA-tailed product. A partially double 
stranded linker cassette with a 5’ T-overhang was then ligated to the ends of the 
purified products using the Fast-Link DNA Ligation kit (Epicentre, Madison, WI; 
LamTlinkerL: 5’ GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTAGGT 3’; LamTlinkerS: 
5' CCTAACTGCTGTGCCACT 3’). Exponential PCR was then performed using the ligation 
product as a template with a biotinylated vector-specific primer for the 5’ or 3’ end of 
the vector and a linker-specific primer (LentiLAM-LC1: 5’ GACCCGGGAGATCTGAATTC 3’). 
Vector-specific PCR products were then enriched using Streptavidin-coated M-280 
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Dynabeads (Invitrogen, Carlsbad, CA). Next, nested PCR using a second MiSeq indexed 
LTR-specific primer for the 5’ or 3’ end and another linker-specific primer (LentiLAM-
LC2: 5’ AGTGGCACAGCAGTTAGG 3’) was performed using the enriched product as a 
template. The final PCR products were then purified using a 1.8:1 ratio of AMPure XP 
beads and quantified using a Qubit Fluorometer (Life Technologies, Grand Island, NY).  
 
5’ LTR Vector-Genome Amplification for 3’ LAM-PCR Verification 
 In order to confirm the vector insertion sites and to aid in elucidating the 
mode of insertion for vectors analyzed by LAM-PCR with Illumina MiSeq analysis off of 
the 3’ LTR, conventional PCR was performed off of the 5’ LTR. Forward genomic primers 
outside of the 5’ LTR were designed using the insertion site determined by 3’ LAM-PCR 
and subsequent sequencing. Reverse primers were designed within the 5’ LTR and 
conventional PCR was performed in order to amplify the 5’ vector-genome junction. The 
resulting PCR products were analyzed by Sanger sequencing.  
 
Sequence analysis 
 Pyrosequencing was performed on a Roche 454 FLX Titanium platform at the 
Indiana University Center for Genomics and Bioinformatics, Bloomington IN. 454 
sequences were analyzed by Troy Hawkins, Ph.D. with the SeqMap 2.0 web server 
platform (Hawkins et al., 2011).  
 Sample libraries sequenced on an Illumina MiSeq platform were performed at 
the Genomics Core Facility of the University of Notre Dame. Paired-end reads of 250 
 85 
 
base-pair were generated. Initial MiSeq analysis and in-house scripts were written by 
Hongyu Gao, Ph.D. In-house scripts were used to de-multiplex the reads and to retain 
paired-end reads that have both perfectly matched viral vector-specific primer and 
linker primer used in the last round of PCR. MiSeq adapter and linker sequences were 
trimmed off with Cutadapt version 1.5 (Martin, 2011). Paired-end reads were merged 
with PEAR version 0.9.5-64 (Zhang, Kobert, Flouri, & Stamatakis, 2014). For the non-
overlapping paired-end reads, the reads containing the viral vector sequence were kept. 
The viral vector sequences in the merged reads were located with cross-match version 
.9909329 (http://www.phrap.org). Reads with less than 30 base-pair viral vector 
sequence and less than 10 base-pair remaining genomic sequence were discarded. The 
remaining reads were further clustered with usearch7.0.1090_i86linux32 (Edgar, 2010). 
Representative reads of each cluster were mapped to human reference genome hg19 
using bwa version 0.7.5a (H. Li & Durbin, 2009). Alignments demonstrating 100% 
sequence identity were designated as integration sites. The cross-match output, cluster 
and mapping information were compiled together in R (RCore, 2012) and further 
analyzed. 
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Figure 18. Overview of LAM-PCR protocol. 1. Capture of integrated vector sequences by 
linear amplification off of 3’ LTR. 2. Purification, selection and double stranding of 
captured vector-genome junctions. 3. Attaching a linker cassette to facilitate 
amplification of vector-genome junctions. 4. Nested PCR amplification to improve 
specificity of vector sequences and facilitate visualization and sequence analysis. 
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C. Results 
 
Capture and analysis of NILV insertion sites by LAM-PCR lacks the sensitivity to 
account for features associated with non-integrase mediated integration 
 NILV offer a unique challenge for the capture and analysis of illegitimate non-
integrase-mediated integrations. Existing PCR-based capture methods for vector 
insertion sites, such as LM-, LAM-, and nrLAM-PCR, utilize primers specific for vector LTR 
sequences to amplify the vector-genome junctions (Figure 18).  The aberrant insertions 
sites observed with NILV include insertion and/or deletions at the vector genome 
junction along with truncations of the vectors LTRs, limiting the efficacy and sensitivity 
of PCR-based capture methods to analyze NILV insertion sites. We have evaluated the 
efficacy of analyzing NILV insertion sites by LAM-PCR. An initial experiment was 
performed with sequencing of LAM-PCR products by Roche 454 pyrosequencing and a 
second more in depth experiment on an Illumina MiSeq platform with subsequent 
confirmation of insertion sites by Sanger sequencing of the 5’ vector-genome junction.  
 The integration competent lentiviral vector (CS-CZW) sequenced by MiSeq 
demonstrated the features associated with integrase-mediated insertion (Table 2). 
Vector insertion sites were identified for 10 of 12 clones at the 3’ vector-genome 
junction. Analysis of the 5’ vector-genome junction was verified for 6 randomly selected 
clones, confirming the insertion sites. The insertions sites displayed the terminal CA 
dinucleotide, indicative of integrase-mediated end-processing, and the five base-pair 
flanking repeat at the vector-genome junctions. 
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 Analysis of integrase-defective NILV have demonstrated non-integrase-
mediated mechanisms of integration such as non-homologous end-joining and 
homologous recombination (Koyama et al., 2013; Matrai et al., 2011; Nightingale et al., 
2006). The resulting insertion and/or deletions at the vector-genome junction can 
inhibit the binding of primers for vector capture. Our initial attempt at analyzing the 
integrase mutant (IN/D116N) by LAM-PCR on the 454 platform allowed for the capture 
of 57% (4 of 7 clones) at the 3’ vector-genome junction (Table 3). All of the captured 
insertion sites demonstrated LTR truncations and insertions/deletions at the junction. 
To verify our results, we repeated this analysis with more clones utilizing the MiSeq 
platform and further verification of insertion sites by conventional PCR and Sanger 
sequencing of the 5’ vector-genome junction in vectors with confirmed 3’ insertion sites. 
With confirmation of 58% (7 of 12 clones) of the insertion sites, there was no 
improvement in capture observed with MiSeq as compared to 454 using this method. Of 
the confirmed insertion sites 57% (4 of 7 clones) displayed the aberrant insertion sites 
associated with NILV integrations. 2 out of the 7 clones with confirmed 3’ insertion sites 
were confirmed by 5’ analysis. Both of the clones displayed the aberrant features 
associated non-integrase-mediated integration, providing confidence to our results 
observed by 454 sequencing. However, only confirming 28% of the 3’ insertion sites 
demonstrates the lack of sensitivity to detect NILV insertions by PCR-based methods 
relying on LTR-specific primers. 
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Table 2. Normal integrating lentiviral vector insertion site analysis demonstrates 
canonical integrase-mediated insertion site features. HEK 293 clones transduced with 
the normal integrating lentiviral vector (CS-CZW) analyzed by LAM-PCR with sequencing 
by Illumina MiSeq. a indicates whether clones analyzed map to a reference genome; 
 b indicates any deletions to the terminal ends of the LTR; c indicates if vectors with 3’ 
confirmation had 5’ vector-genome junction analysis performed; d indicates the 
presence of a 5 base-pair flanking repeat at the vector-genome junctions of vectors with 
5’ and 3’ confirmation. Empty cells indicate the clone was not selected for 5’ analysis. 
 
 
 
 
 
Clone
3' IS 
Identifieda
3' LTR 
Truncationsb
5' Confirmation 
Performed?c
5' IS 
Identifieda
5' LTR 
Truncationsb
5-bp 
Repeatd
m1 Yes No Yes Yes No Yes
m2 No No No
m3 Yes No No
m4 Yes No Yes Yes No Yes
m5 Yes No Yes Yes No Yes
m6 Yes No No
m7 Yes No Yes Yes No Yes
m8 Yes No No
m9 Yes No Yes Yes No Yes
m10 No No No
m11 Yes No Yes Yes No Yes
m12 Yes No No
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Table 3. Integrase defective mutant NILV insertion site analysis demonstrates features 
associated with non-integrase-mediated insertion. HEK 293 clones transduced with the 
integrase defective NILV (IN/D116N) analyzed by LAM-PCR with sequencing by Illumina 
MiSeq. a indicates whether clones analyzed map to a reference genome; 
 b indicates any deletions to the terminal ends of the LTR; c indicates if vectors with 3’ 
confirmation had 5’ vector-genome junction analysis performed; d indicates the 
presence of genomic deletions or insertions at the vector-genome junctions; e indicates 
the presence of a 5 base-pair flanking repeat at the vector-genome junctions of vectors 
with 5’ and 3’ confirmation. Empty cells indicate 3’ or 5’ insertion site was not identified 
and additional analysis was not able to be performed. 
 
 
Clone
Sequencing 
Platform
3' IS 
Identifieda
3' LTR 
Truncationsb
5' Confirmation 
Performed?c
5' IS 
Identifieda
5' LTR 
Truncationsb
Junction 
INDELsd
5-bp 
Repeate
r1 Roche 454 No
r2 Roche 454 No
r3 Roche 454 Yes Yes No Yes
r4 Roche 454 Yes Yes No Yes
r5 Roche 454 No
r6 Roche 454 Yes Yes No Yes
r7 Roche 454 Yes Yes No Yes
m13 Illumina MiSeq No
m14 Illumina MiSeq No
m15 Illumina MiSeq Yes Yes Yes Yes Yes Yes No
m16 Illumina MiSeq Yes Yes Yes Yes No Yes No
m17 Illumina MiSeq No
m18 Illumina MiSeq Yes No Yes No Yes
m19 Illumina MiSeq Yes No Yes No No
m20 Illumina MiSeq Yes No Yes No No
m21 Illumina MiSeq Yes No Yes No No
m22 Illumina MiSeq Yes Yes Yes No No
m23 Illumina MiSeq No
m24 Illumina MiSeq No
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 The Roche 454 sequence analysis of our novel LTRΔatt NILV was able to 
identify insertion sites in 50% (4 of 8) of clones using 3’ LAM-PCR (Table 4). The results 
revealed intact 3’ LTRs in 75% (3 of 4 clones) of these. However, 75% of these 4 verified 
3’ insertion sites presented insertions at the 5’ vector genome junction ranging from 5-
168 base-pairs. The MiSeq analysis of LTRΔatt clones was able to confirm 73% of the 3’ 
insertions sites. Only one of the 3’ confirmed insertions sites revealed a truncation of 
the LTR and none presented insertions or deletions at the vector-genome junction. Only 
two of the 3’ confirmed insertions sites were able to be further confirmed by 5’ analysis. 
These two clones both presented insertions and deletions at the 5’ vector-genome 
junction and one of them indicated the presence of a flanking 5 base-pair repeat of 
genomic DNA. These results indicated that the LTRΔatt vector was demonstrating 
features of integrase-mediated insertion at the 3’ vector-genome junction while 
presenting aberrant insertion at the 5’ LTR junction.  
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Table 4. U3 LTR integrase DNA attachment site deleted NILV insertion site analysis 
demonstrates features associated with both integrase- and non-integrase-mediated 
insertion. HEK 293 clones transduced with the U3 attachment site deleted NILV 
(LTRΔatt) analyzed by LAM-PCR with sequencing by Illumina MiSeq. a indicates whether 
clones analyzed map to a reference genome; b indicates any deletions to the terminal 
ends of the LTR; c indicates if vectors with 3’ confirmation had 5’ vector-genome 
junction analysis performed; d indicates the presence of genomic deletions or insertions 
at the vector-genome junctions; e indicates the presence of a 5 base-pair flanking repeat 
at the vector-genome junctions of vectors with 5’ and 3’ confirmation; * insertions and 
deletions were only present at the 5’ LTR vector-genome junction. Empty cells indicate 
3’ or 5’ insertion site was not identified and additional analysis was not able to be 
performed. 
 
Clone
Sequencing 
Platform
3' IS 
identifieda
3' LTR 
Truncationsb
5' Confirmation 
Performed?c
5' IS 
Identifieda
5' LTR 
Truncationsb
Junction 
INDELsd
5-bp 
Repeate
r8 Roche 454 No
r9 Roche 454 Yes No No Yes
r10 Roche 454 Yes No No No
r11 Roche 454 No
r12 Roche 454 Yes Yes No Yes
r13 Roche 454 Yes No No Yes
r14 Roche 454 No
r15 Roche 454 No
m25 Illumina MiSeq Yes No Yes No
m26 Illumina MiSeq Yes No Yes No
m27 Illumina MiSeq Yes No Yes No
m28 Illumina MiSeq No
m29 Illumina MiSeq Yes No Yes No
m30 Illumina MiSeq Yes No Yes Yes Yes Yes* Yes
m31 Illumina MiSeq Yes Yes Yes No
m32 Illumina MiSeq No
m33 Illumina MiSeq Yes No Yes No
m34 Illumina MiSeq Yes No Yes Yes Yes Yes* No
m35 Illumina MiSeq No
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 We have previously demonstrated that combining the LTRΔatt and IN/D116N 
mutations was able to significantly reduce the frequency of illegitimate integration as 
compared to either of these mutations independently (Figure 11). Our conclusion 
elucidated from the results in Table 4 indicate that the LTRΔatt mutation in the presence 
of a functional integrase protein can still bind to integrase at the intact U5 attachment 
site and facilitate integrase mediated insertion of the vectors 5’ LTR. The double mutant 
vector would combine the attachment site deletion with an integrase protein defective 
for strand transfer and integration. Our sequencing of LAM-PCR results by MiSeq and 
454 sequencing demonstrate the increased efficacy of inhibiting integration by the 
LTRΔatt-IN/D116N combination. We were able to confirm two of four 3’ insertion sites 
by 454 sequencing, with both clones demonstrating the features associated with non-
integrase-mediated insertion. Our MiSeq results for this vector were only able to 
identify vector insertion sites in 22% (2 of 9) of the analyzed clones for 3’ insertion sites 
and we were unable to confirm any of the corresponding 5’ insertion sites. The 
confirmed vectors displayed completely intact LTRs without the two base-pair 
truncation indicative of integrase-mediated end-processing. These limited results 
demonstrate that the inclusion of the integrase mutation in combination with the 
LTRΔatt mutation results in features similar to the IN/D116N vector, indicating the 
inhibition of features associated with integrase-mediated insertion at the 3’ vector-
genome junction as observed with LTRΔatt. They also demonstrate a lack of sensitivity 
to significantly analyze NILV clones using PCR-based techniques relying on intact LTR 
sequences for vector capture. 
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Table 5. Double mutant NILV insertion site analysis demonstrates features associated 
with non-integrase-mediated insertion. HEK 293 clones transduced with the double 
mutant NILV (LTRΔatt-IN/D116N) analyzed by LAM-PCR with sequencing by Illumina 
MiSeq. a indicates whether clones analyzed map to a reference genome; b indicates any 
deletions to the terminal ends of the LTR; c indicates if vectors with 3’ confirmation had 
5’ vector-genome junction analysis performed; d indicates the presence of genomic 
deletions or insertions at the vector-genome junctions; e indicates the presence of a 5 
base-pair flanking repeat at the vector-genome junctions of vectors with 5’ and 3’ 
confirmation. * 2 base-pair insertions indicating a lack of end-processing mediated by 
the integrase protein. Empty cells indicate 3’ or 5’ insertion site was not identified and 
additional analysis was not able to be performed. 
 
 
 
 
Clone
Sequencing 
Platform
3' IS 
Identifieda
3' LTR 
Truncationsb
5' Confirmation 
Performed?c
5' IS 
Identifieda
5' LTR 
Truncationsb
Junction 
INDELsd
5-bp 
Repeate
r16 Roche 454 Yes Yes No Yes
r17 Roche 454 No
r18 Roche 454 Yes Yes No Yes
r19 Roche 454 No
m36 Illumina MiSeq No
m37 Illumina MiSeq No
m38 Illumina MiSeq No
m39 Illumina MiSeq No
m40 Illumina MiSeq No
m41 Illumina MiSeq No
m42 Illumina MiSeq Yes No Yes No Yes*
m43 Illumina MiSeq Yes No Yes No Yes*
m44 Illumina MiSeq No
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Modified insertion site analysis improves the sensitivity for capturing non-integrase- 
mediated integrations by NILV 
 The lack of sensitivity observed when using LAM-PCR for the capture and 
analysis of aberrant insertions sites associated with NILV led us to explore other 
methodologies which would provide more flexibility for improving our analysis. Recent 
reports have demonstrated a method utilizing sonication of transduced DNA in order to 
produce fragments of a manageable size which would allow for ready manipulation and 
amplification (De Ravin et al., 2014; S. Zhou et al., 2014). We sought to modify this 
methodology to improve our analysis by accounting for the high frequency of 
truncations to NILV LTRs (Figure 19). (1) We began with a sonication program for the 
production of larger fragments to allow for capture and further purification of 
integrated vector sequences. (2) Linker cassettes were ligated onto the ends of the 
fragmented genome. (3) We began our initial capture with primers set outside of the 
LTR in the vector sequence to compensate for the occurrence of deletions. Nested PCR 
was performed to increase specificity and to keep the amplicons within a size range 
which would allow for complete coverage by paired-end sequencing. These 
modifications permit up to approximately 280 base-pair LTR deletions without affecting 
sensitivity. Sequence results of the IN/D116N integrase mutant supported our previous 
findings and those reported by others (Table 6). Sequencing produced an average of 
171K reads per clone. The modified methodology was able to improve the capture of 
insertions sites from ~58% by LAM-PCR to 83%. The majority of the insertion sites 
demonstrated large LTR truncations that would have inhibited capture by LAM-PCR. 
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Figure 19. Modified insertion site analysis methodology. Insertion site analysis of 
selected vector transduced clones intended to improve the capture of NILV insertion 
sites as described in the text.  
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Table 6. Modified insertion site methodology demonstrates improved sensitivity for 
the analysis of Integrase defective NILV integrations. HEK 293 clones transduced with 
an integrase defective NILV (IN/D116N) analyzed by a modified vector insertion site 
methodology with sequencing by Illumina MiSeq. a indicates reads map to a reference 
genome meeting filtering criteria; b size of deletions (base-pairs) to the terminal ends of 
the LTR; c length of insertions in base-pairs detected at the vector-genome junction; d 
indicates the 3’ and 5’ confirmed reads map to the same genomic location; e indicates 
the presence of any genomic DNA deletions at the vector-genome junction; f indicates 
the presence of a 5 base-pair flanking repeat at the vector-genome junctions. Empty 
cells indicate 3’ or 5’ insertion site was not identified and additional analysis was not 
able to be performed. 
 
 
 
Clone
3' IS 
Ident.
a
3' LTR 
Trunc.
b
3' 
Insert.
c
5' IS 
Ident.
a
5' LTR 
Trunc.
b
5' 
Insert.
c
3' & 5' 
Paired
d
Genomic 
Deln.
e
5-bp 
Repeat
f
c1 Yes 2 0 Yes 0 0 Yes Yes No
c2 Yes 125 4 Yes 215 0 No
c3 Yes 0 3 Yes 241 4 No
c4 No No No
c5 Yes 138 42 Yes 235 41 No
c6 Yes 170 36 Yes 226 45 No
c7 Yes 0 8 Yes 0 0 Yes Yes No
c8 Yes 0 0 Yes 10 0 Yes Yes No
c9 Yes 8 0 Yes 11 0 Yes Yes No
c10 Yes 170 40 Yes 111 83 No
c11 No No No
c12 Yes 9 0 Yes 159 98 No
 98 
 
 Sequencing results from modified insertion site analysis of the novel U3 LTR 
attachment site deleted NILV (LTRΔatt) also support our LAM-PCR results (Table 7). The 
results strongly support our hypothesis that a functional integrase protein is able to bind 
to the intact U5 attachment site and facilitate integration at the 3’ LTR, while ablation of 
the U3 attachment site results in aberrant insertion at the 5’ LTR. This was evident as 
only 11% (1 of 9) of the confirmed 3’ insertion sites presents a truncation of the LTR, 
while 100% of the confirmed 5’ insertion sites demonstrate the large deletions and 
insertions associated with non-integrase-mediated integration. However, while these 
results are promising, there was no improvement in the percentage of clones confirmed 
by this method. Further optimization of this methodology and a larger sample size could 
improve the capture of vector insertion sites.  
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Table 7. Modified insertion site methodology supports PCR-based insertion site 
capture results, identifying a unique mode of integration by a novel U3 LTR integrase 
attachment site mutant NILV. HEK 293 clones transduced with a novel U3 LTR 
attachment deleted NILV (LTRΔatt) analyzed by a modified vector insertion site 
methodology. a indicates reads map to a reference genome meeting filtering criteria; b 
size of deletions (base-pairs) to the terminal ends of the LTR; c length of insertions in 
base-pairs detected at the vector-genome junction; d indicates the 3’ and 5’ confirmed 
reads map to the same genomic location; e indicates the presence of any genomic DNA 
deletions at the vector-genome junction; f indicates the presence of a 5 base-pair 
flanking repeat at the vector-genome junctions. Empty cells indicate 3’ or 5’ insertion 
site was not identified and additional analysis was not able to be performed. 
 
Clone
3' IS 
Ident.
a
3' LTR 
Trunc.
b
3' 
Insert.
c
5' IS 
Ident.
a
5' LTR 
Trunc.
b
5' 
Insert.
c
3' & 5' 
Paired
d
Genomic 
Deln.
e
5-bp 
Repeat
f
c13 Yes 212 0 Yes 242 72 Yes Yes No
c14 Yes 0 0 Yes 208 0 No
c15 Yes 0 0 Yes 225 14 No
c16 Yes 0 0 No No
c17 No No No
c18 No No No
c19 Yes 0 0 Yes 242 68 No
c20 No No No
c21 No No No
c22 No No No
c23 No No No
c24 No No No
c25 No Yes 229 0 No
c26 Yes 0 0 No No
c27 Yes 0 0 No No
c28 Yes 0 0 Yes 233 0 No
c29 Yes 0 0 Yes 193 4 No
c30 No Yes 232 0 No
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 Our previous results when analyzing the insertion sites of the double mutant 
vector (LTRΔatt-IN/D116N) yielded a very low frequency of clones we were able to 
confirm. It was likely that the inclusion of both mutations for inhibiting integration 
resulted in a higher frequency of aberrant insertion sites with large LTR truncations 
which may have prevented the capture by LAM-PCR. The modified insertion site analysis 
resulted in a significantly improved yield of LTRΔatt-IN/D116N clones we were able to 
confirm. Similar to the LTRΔatt insertion sites, the double mutant presented aberrant 5’ 
vector-genome junctions in 93% of confirmed clones. However, unlike the LTRΔatt 
mutant, the 3’ LTR junction demonstrated aberrations in 100% of the clones analyzed. 
Though, 50% of these presented with insertions and no truncations to the vectors LTR.  
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Table 8. Double mutant NILV demonstrate increased frequencies of aberrations at 
vector insertions sites relative to independent mutations. HEK 293 clones transduced 
with a double mutant NILV (LTRΔatt-IN/D116N) analyzed by a modified vector insertion 
site methodology with sequencing by Illumina MiSeq. a indicates reads map to a 
reference genome meeting filtering criteria; b size of deletions (base-pairs) to the 
terminal ends of the LTR; c length of insertions in base-pairs detected at the vector-
genome junction; d indicates the 3’ and 5’ confirmed reads map to the same genomic 
location; e indicates the presence of any genomic DNA deletions at the vector-genome 
junction; f indicates the presence of a 5 base-pair flanking repeat at the vector-genome 
junctions; * analysis detected an aberrant 80 base-pair repeat flanking the vector. 
 
Clone
3' IS 
Ident.a
3' LTR 
Trunc.b
3' 
Insert.c
5' IS 
Ident.a
5' LTR 
Trunc.b
5' 
Insert.c
3' & 5' 
Pairedd
Genomic 
Deln.e
5-bp 
Repeatf
c31 Yes 5 5 Yes 0 0 Yes No No*
c32 Yes 196 43 Yes 170 0 No
c33 Yes 191 0 Yes 232 0 No
c34 Yes 0 74 Yes 215 139 No
c35 No No No
c36 Yes 1 3 Yes 214 0 No
c37 No No No
c38 No No No
c39 Yes 0 18 Yes 231 0 No
c40 No No No
c41 No Yes 222 0 No
c42 No No No
c43 Yes 0 14 Yes 215 201 No
c44 Yes 0 18 Yes 215 49 No
c45 Yes 2 2 Yes 161 7 Yes Yes No
c46 Yes 0 32 Yes 163 2 No
c47 Yes 0 7 Yes 0 18 Yes No No
c48 No No No
c49 Yes 4 12 Yes 229 1 No
c50 No No No
c51 No No No
c52 No Yes 229 15 No
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D. Discussion 
 
 The studies presented here demonstrate the necessity for the optimization of 
methodologies for the analysis of illegitimate integrations by NILV. The novel LTRΔatt 
vector has demonstrated a significant reduction in the frequency of illegitimate 
integration when combined with an integrase catalytic core mutation (IN/D116N) as 
compared to either of these independently (Figure 11). We sought to characterize the 
insertion sites of clones transduced with NILV containing these mutations in order to 
discern the mechanisms of integration leading to the variability observed in integration 
between them and the improved profile when combined. Existing methodologies for 
analyzing vector insertion sites rely upon capture and amplification using primers at the 
vector-genome junction. As we have demonstrated here, this presents limitations when 
analyzing NILV which integrate by non-integrase-mediated mechanisms, such as NHEJ 
and HR, resulting in LTR truncations and insertions/deletions at the vector-genome 
junction. We have demonstrated that modifying insertion site capture methods to 
account for these variations can improve the analysis of NILV. 
 Our results demonstrate the canonical features associated with the types of 
vectors used (Figure 20). As was expected, integrase-mediated insertion was prominent 
when using an integration competent vector. We have shown our integrase defective 
NILV to display illegitimate integration features indicative of non-integrase-mediated 
insertion, similar to reports by others when using integrase catalytic core mutants 
(Matrai et al., 2011; Nightingale et al., 2006).  
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 Our novel LTRΔatt vector demonstrates a unique mode of illegitimate 
integration at one end of the vector. The deletion of the U3 attachment site at the 
terminal end of the 5’ LTR appears to effectively inhibit integrase binding and insertion. 
However, our results suggest that integrase can still bind with the intact U5 attachment 
site at the 3’ LTR. Integrase binding appears to stabilize this terminal end of the vector 
and/or facilitate integration into the host genome, indicated by the lack of 3’ LTR 
truncations observed and indications of integrase-mediated end-processing (Table 7).  
 As combining the attachment site and integrase mutations leads to a 
significant reduction in integration frequency, we expect the defective integrase protein 
would inhibit the features associated with strand-transfer at the 3’ LTR. The combined 
LTRΔatt-IN/D116N NILV demonstrates similar features to LTRΔatt at the 5’ LTR, with 
large LTR truncations and insertions/deletions at the vector genome junction. Inclusion 
of the integrase mutation resulted in the presence of features at the 3’ LTR indicative of 
non-integrase mediated insertion, similar to the IN/D116N mutation independently. 
Interestingly, it was observed that insertions at the 5’ LTR of clones transduced with 
vector containing the ablated U3 attachment site demonstrated significantly more and 
larger LTR truncations than were observed for the 3’ LTR with its intact U5 attachment 
site regardless of integrase inhibition. Common mutations to produce integrase-
defective NILV introduce missense mutations to a triad of residues at the catalytic core 
of integrase that inhibit strand-transfer (Kulkosky et al., 1992; Shibagaki & Chow, 1997). 
These mutations do not inhibit the ability of integrase to bind vector DNA, which is 
controlled by a Q148 residue in the core domain of integrase (Esposito & Craigie, 1998; 
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Gerton, Ohgi, Olsen, DeRisi, & Brown, 1998). Thus, it appears that in the presence of 
intact LTR integrase attachment sites, integrase mutants retain the ability to bind vector 
DNA stabilizing the terminal ends and inhibiting degradation resulting in fewer 
truncations of vector LTR sequences.  
 In summary, these results demonstrate that improving methods to analyze 
the aberrant insertion sites of NILV will require capture and amplification strategies 
which can compensate for insertions and deletions at the vector-genome junctions. 
With further optimization our modified in insertion site analysis method should enable 
the capture of the majority of NILV insertions as may be required for FDA approval to 
get NILV into the clinic. Our findings illustrate the characteristics of our novel U3 LTR 
attachment site mutation for inhibiting integration and how combination with integrase 
mutations can improve its inhibition of integrase-mediated insertion. This demonstrates 
the feasibility of combining other mutations to further improve the utility of NILV. 
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Figure 20. Overview of vector-genome junction features of vector transduced clones. 
Summary of our results obtained from sequencing of Zeocin selected clones transduced 
with a normal integrating vector (CS-CZW), an integrase catatlytic core mutant NILV 
(IN/D116N), a U3 LTR integrase attachment sited deleted NILV (LTRΔatt) and a double 
mutant (LTRΔatt-IN/D116N). Red highlighted base-pairs indicate flanking 5-bp repeat of 
genomic DNA by integrase-mediated strand-transfer; underlined TG/CA dinucleotides 
represent end-processing by a function integrase protein; inverted black triangles 
represent LTR truncations; red highlighted triangle represents deletions of genomic 
DNA; black squares indicate insertions at the vector-genome junction.
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V. Conclusions 
 
 The use of viral vectors for the gene therapy treatment of patients poses 
inherent risks associated with biological tools discovered by their ability to induce 
disease. Early clinical trials utilizing gamma retroviral vectors have resulted in adverse 
events to patients induced by insertional mutagenesis, highlighting these risks. Lentiviral 
vector mediated gene therapy has been explored as a safer alternative to early gamma 
retroviral vectors and have demonstrated an improved profile relative to the risk of 
insertional mutagenesis. As these vectors have begun to enter various clinical trials it is 
imperative to ensure that we provide the safest product possible when treating 
patients. The necessity for improving vector safety ranges from the production of vector 
supernatant, the design and safety profile of the vectors used for transduction, to follow 
up analysis of vector transduced cells. We have evaluated an FDA approved DNase for 
improving the purity of lentiviral vector supernatant, developed a novel NILV to improve 
the utility of these vectors for clinical use, and modified insertion site analysis methods 
to improve the capture of aberrant insertion sites associated with illegitimate NILV 
integration.  
 Lentiviral vector production utilizes a transient transfection of producer cell 
lines, such as HEK 293T, with a four plasmid system. This system places the vector 
components in trans to each other in order to reduce the risk of recombination and the 
production of a replication competent vector. In order to further reduce the risk of 
recombination and the exposure of patients to viral DNA, residual plasmid DNA must be 
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thoroughly removed following transfection. Here we have demonstrated the application 
of Pulmozyme, a recombinant human DNase FDA approved for treating cystic fibrosis 
patients (Pan et al., 2001; Shak et al., 1990; Shire, 1996; Ulmer et al., 1996). Pulmozyme 
was investigated as an alternative to Benzonase, a bacterially derived DNase. While 
Pulmozyme was determined to be an effective, clinically relevant alternative to 
Benzonase, the possibility of residual DNase in the vector supernatant could pose a risk 
to patients. Adverse events due to Pulmozyme are rare and it has been shown to rapidly 
degrade in serum with a half-life of three to four hours (Roche, 2014). However, gene 
therapy of immune-compromised individuals would require increased purity of vector 
supernatant to prevent adverse effects from residual production components. In order 
to produce clinical grade vector supernatant it will be necessary to implement 
downstream processing to remove impurities and to include detection of residual DNase 
along with the rigorous testing already mandated prior to clinical application.  
 Development of the novel LTRΔatt NILV demonstrated reductions in 
integration frequency inferior to integrase defective NILV. However, when combined, 
these two mutations significantly reduced the frequency of integration relative to either 
independently. Combining these two mutations with a 3’ PPT deletion to further inhibit 
integration and a large U3 deletion of cis-acting inhibitors to transgene expression 
resulted in an improvement in transgene expression levels while significantly reducing 
the frequency of illegitimate integration. This provided an important proof of concept 
for improvement of NILV to increase their clinical utility. 
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In order to further characterize the novel LTRΔatt vector, we sought to sequence the 
vector insertion sites in order to elucidate the mechanism resulting in the increased 
illegitimate integration relative to the IN/D116N integrase defective NILV. However, as 
we and others have demonstrated (Gaur & Leavitt, 1998; Matrai et al., 2011; 
Nightingale et al., 2006), NILV insertion sites demonstrate aberrant vector-genome 
junctions which can inhibit their capture by PCR-based methods utilizing primers within 
the LTRs for amplification. We sought to modify a method of vector insertion site 
capture utilizing sonication of the transduced vector genome (De Ravin et al., 2014; S. 
Zhou et al., 2014) prior to initial vector capture. Implementing this new methodology 
along with our modifications, significantly improved our ability to capture and analyze 
NILV insertion sites. Further optimization of this methodology will allow for even more 
improvement in the capture of NILV insertion sites for analysis. Possible modifications 
include increasing the specificity to reduce the capture of non-specific sequences and 
improved capture of vector-containing fragments. To improve the capture of NILV 
insertion sites it may be possible to devise a pull down to capture or bind all fragments 
containing vector sequences. These fragments could then be amplified indiscriminately 
utilizing terminal linker cassette/adapter sequences, thus eliminating the necessity to 
rely upon primers near the variable vector-genome junctions of NILV. This methodology 
would require an increased bioinformatics analysis in order to filter and analyze reads 
containing vector-genome junctions. These optimizations could theoretically improve 
our ability to analyze aberrant NILV insertion sites increasing the clinical utility of these 
vectors by allowing for more sensitive analysis of transduced cells post-transduction. 
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 Taken in aggregate, our sequencing results demonstrate the expected 
features for our normal integrating vector (CS-CZW) and the integrase-defective mutant 
NILV (IN/D116N), in line with previous reports. Our novel LTRΔatt NILV demonstrated 
features unique to this particular mutant. Our results indicate that deletion of the U3 
LTR integrase attachment site effectively inhibits integrase protein binding at the 
terminal end of the vectors 5’ LTR. Sequencing of the 3’ insertion sites indicate that the 
presence of an intact U5 attachment site at the vectors 3’ LTR allows for integrase 
binding and insertion at this end. The 5’ end is then subsequently integrated likely by 
non-homologous end-joining resulting in the large truncations at the terminal end of the 
LTR and insertions/deletions of the adjacent genomic DNA. Combining the LTRΔatt and 
IN/D116N mutations confirms these findings. The presence of the integrase mutation 
results in an increased frequency of aberrant features at the 3’ LTR vector-genome 
junction similar to those observed with the IN/D116N NILV independently. However, a 
significantly lower frequency of LTR truncations in the presence of only the IN/D116N 
mutation indicate that integrase is still able to bind the intact attachment sites and 
stabilize the ends from degradation prior to non-integrase-mediated insertion. These 
results indicate that including functional mutations to the U5 attachment site along with 
the LTRΔatt and IN/D116N mutations may further reduce the frequency of integration 
by NILV. As complete ablation of the U5 attachment site does not result in viable 
vectors, the inclusion of point mutations, similar to those previously reported (Apolonia 
et al., 2007; Nightingale et al., 2006), could provide improved inhibition of integration. 
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These results demonstrate how elucidating the features associated with illegitimate 
integration by NILV can improve their design for use in the clinic. 
 Possible improvements to this line of work include the development of assays 
to evaluate the presence of residual DNase enzymes in the final vector supernatant 
product for clinical applications. An enzyme-linked immunosorbent assay, with 
antibodies to DNase I, could provide for a method to satisfy this necessity. 
  As described above, further optimization of methods is necessary to improve 
the capture of aberrant insertion sites associated with NILV integrations. Improving the 
sensitivity to analyze NILV insertion sites will increase the utility of these vectors for use 
in the clinic.  
 Sequencing and integration analysis results demonstrate the utility of 
combining modifications to reduce the frequency of illegitimate integration by NILV. 
Sequence results demonstrating the absence of any integrase-mediated integration 
features at LTRs with ablated attachment sites present the possibility of including an 
additional mutation to the U5 LTR integrase attachment site to further reduce the 
frequency of integration by NILV.  
 To further improve NILV utility these modifications could be combined with 
inhibition of cellular restriction factors to transgene expression which have been shown 
to improve NILV episomal transgene expression to levels associated with integration 
competent vectors (Berger et al., 2009; Negri et al., 2012; Pelascini et al., 2013). The 
production of an NILV with optimal transgene expression would provide for a safer 
vector for clinical use by decreasing the volume of vector necessary to provide a 
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therapeutic benefit. Decreasing the quantity of vector required for gene therapy 
applications translates to a decreased risk of illegitimate integrations leading to 
insertional mutagenesis. Combining this with multiple modifications for effectively 
inhibiting integrase-mediated insertion would result in an optimal NILV for use. 
 In conclusion, this study highlights how continuous improvements can 
advance the safety of lentiviral vector mediated gene therapy. Reducing the impurities 
in vector supernatant, providing the safest vector possible, and improving the sensitivity 
for analyzing vector insertion sites post-treatment will help to move lentiviral vectors 
forward as they continue to enter the clinic. 
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VI. Future Direction 
“Adapted from Shaw A, Cornetta K. Design and Potential of Non-Integrating Lentiviral 
Vectors. Biomedicines. 2014; 2(1):14-35” 
 
 We have demonstrated significant improvements in expression and the 
reduction of illegitimate integration when combining modifications to NILV design. We 
have shown that combining a novel U3 LTR integrase DNA attachment site deletion with 
an in integrase mutation (D116N), a deletion of the 3’ PPT, and a large deletion of the 
U3 region demonstrates improved transgene expression and reduced illegitimate 
integration as compared to current NILV. This novel combination of NILV mutations 
provides an optimal vector for many clinical applications. 
 There are many clinical applications which could benefit from our optimized 
NILV with its improved safety profile. These applications include vaccinations, cell-type 
and lineage differentiation, as donor templates for homologous recombination in site-
directed integration systems, and as delivery systems for cytotoxic cancer therapies. 
NILV are also being considered for gene transfer into slowly growing or non-dividing 
tissues where persistent episomal expression can provide a long-lasting therapeutic 
effect. 
 Vaccination is an application where only transient expression is required and 
NILVs have been shown to stimulate an efficient and sustained immune response 
(Daenthanasanmak et al., 2012; Hu, Dai, & Wang, 2010; Michelini et al., 2009; Negri et 
al., 2012). Preclinical studies of NILVs have demonstrated immune responses against 
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human papillomavirus (HPV), malaria, HIV-1 and the hepatitis B and C viruses (Coutant 
et al., 2008; Coutant et al., 2012; Deng et al., 2013; Grasso et al., 2012; Karwacz et al., 
2009; Negri et al., 2007) thus showing their potential for use in vaccine development. 
 A second application where transient expression is preferred over sustained 
expression is in cell reprogramming. This includes creation of induced pluripotent stem 
(iPS) cells and differentiation of iPS or embryonic stem (ES) cells into a lineage of 
interest. While somatic cells have been successfully reprogrammed into iPS cells using 
integrating vectors (Papapetrou et al., 2009), the factors for inducing pluripotency are 
not necessary beyond initial reprogramming and constitutive expression of the factors 
has been shown to be harmful (Okita, Ichisaka, & Yamanaka, 2007; Papapetrou et al., 
2009; Takahashi et al., 2007; Wernig et al., 2007). Continued expression can be 
oncogenic (Okita et al., 2007) and can also affect differentiation of iPS cells into other 
lineages (Soldner et al., 2009). Transgene free iPS cells have been produced using 
integrating LV followed by excision with NILVs expressing Cre recombinase after 
reprogramming (Papapetrou & Sadelain, 2011) as well as by transient expression using 
both non-integrating adenoviral vectors (Stadtfeld, Nagaya, Utikal, Weir, & 
Hochedlinger, 2008; Yu et al., 2009) and NILV (Mali et al., 2008). NILV have also been 
successful in differentiating ES cells into specific progenitors (Yang et al., 2013).  
 Another promising application for NILV is their use as templates for site-
directed integration systems. A variety of systems are available that can direct 
integration to genomic “safe loci” or by altering the integration pattern to avoid 
transcriptional units with the hope of minimizing gene dysregulation. Integration can be 
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directed to sequence-specific motifs in less intragenic regions by combining NILVs with 
an integrase protein fused to a DNA-binding protein such as the E. coli LexA repressor 
(Goulaouic & Chow, 1996; Holmes-Son & Chow, 2000, 2002) or a synthetic polydactyl 
zinc finger protein E2C (Tan, Dong, Wilkinson, Barbas, & Chow, 2006). Another approach 
is combining recombinases or transposases transiently with NILV to facilitate integration 
at specific sites (Moldt et al., 2011; Moldt, Staunstrup, Jakobsen, Yanez-Munoz, & 
Mikkelsen, 2008; Vink et al., 2009). Third, NILVs can be designed to promote site specific 
homologous recombination (HR) (Okada et al., 2009). Taking this a step farther, others 
have combined NILV with a rare cutting nuclease for targeted recombination at specific 
sites by HR (Cornu & Cathomen, 2007). Still others have used NILV as templates for HR 
along with engineered zinc finger nucleases (ZFNs) or transcription activator-like 
effector nucleases (TALENs) (Joglekar et al., 2013; Lombardo et al., 2011; Lombardo et 
al., 2007; Osborn et al., 2013). Increasing clinical utility is expected as these systems are 
optimized to reduce off-target integrations and increase the efficiency of delivery. 
 NILV have potential utility in cytotoxic cancer therapies. One approach takes 
advantage of abnormal expression levels of miRNA which are found in many tumor 
types (Calin & Croce, 2006). In vitro and in vivo studies have shown some miRNAs to 
have antitumorigenic properties (Ventura & Jacks, 2009). Recent studies have shown 
the utility of non-integrating adeno-associated virus in suppressing tumor growth in lung 
(Esquela-Kerscher et al., 2008; Kumar et al., 2008) and liver cancers (Hsu et al., 2012; 
Kota et al., 2009). Non-integrating vectors offer the advantage of minimizing effects 
from transgene expression in normal cells. This targeting of miRNA provides the 
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backdrop for developing NILV for similar applications, whose lower levels of transgene 
expression may be advantageous as too much miRNA can inadvertently kill off-target 
cells. We have initiated the development of an NILV for these applications containing 
our novel modifications. We have inserted a microRNA into our novel vector 
combination in order to test its utility for cytotoxic cancer therapy of the liver. RT-Q-PCR 
analysis demonstrated that our vector was able to provide approximately a 50X fold 
increase in miR-122 expression in HEK 293 cells. Initial testing was initiated in various 
hepatic carcinoma cell lines including Hep-G2, Hep-3B, SNU-449 and Hepa-1c1c7.  
 While there are many applications for transient expression of NILV, there is 
also great promise in their utilization for persistent episomal expression in non-
proliferating post-mitotic cells. In this regard, NILV have been found to successfully 
provide long-lasting in vivo expression in several organs. Injections of integrase deficient 
LV and att site mutant NILV into mouse muscle were found to provide levels of 
transgene expression similar to wild-type LV for up three months post-transduction 
(Apolonia et al., 2007). NILV have also been used to transduce the liver resulting in 
stable transgene expression for up to six months (Bayer et al., 2008) and could provide 
therapeutic levels of transgene expression (Cantore et al., 2012; Matrai et al., 2011). The 
retina transduced with NILVs has been shown to provide transgene expression for up to 
nine months in mice (Yanez-Munoz et al., 2006). NILV were used to successfully 
transduce the brain and spinal cord allowing for efficient transgene expression from 2 
weeks up to 4 months post-transduction (Kantor et al., 2011; Peluffo et al., 2013; 
Philippe et al., 2006; Rahim et al., 2009; Yanez-Munoz et al., 2006). This list is by no 
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means conclusive and as new technologies are developed optimized NILV will continue 
to provide a safe, flexible platform for clinical applications. 
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